MaldenExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	•				•		
	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	33.05	32	97	Male	21.80	19	87
Female	15.17	21	138	Female	19.16	18	94
Total	48.23	53	110	Total	40.96	37	90
Brain and Other Ce	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	9.66	10	104	Male	6.27	9	144
Female	8.81	9	102	Female	6.51	4	NC*
Total	18.47	19	103	Total	12.78	13	102
<u>Breast</u>				Non-Hodgkin('s) Ly	<u>mphoma</u>		
Male	1.51	1	NC*	Male	26.65	34	128
Female	221.63	220	99	Female	27.86	20	72
Total	223.15	221	99	Total	54.51	54	99
Cervix Uteri				Oral Cavity and Pha	<u>ırynx</u>		
				Male	19.59	23	117
Female	12.99	18	139	Female	11.26	12	107
				Total	30.85	35	113
Colon / Rectum				Ovary			
Male	81.70	88	108				
Female	95.60	100	105	Female	25.95	23	89
Total	177.31	188	106				
Esophagus				<u>Pancreas</u>			
Male	11.35	13	115	Male	13.66	10	73
Female	4.65	6	129	Female	17.40	9	52 #-
Total	16.00	19	119	Total	31.05	19	61 #-
Hodgkin's Disease				Prostate	000		.
Male	5.30	6	113	Male	196.06	191	97
Female	4.60	3	NC*	Maio	100.00	101	01
Total	9.90	9	91				
Kidney and Renal F		J	31	Stomach			
Male	18.65	31	166 #+	Male Male	13.92	13	93
Female	13.66	18	132	Female	10.55	17	161
Total	32.31	49		Total	24.47	30	123
	32.31	49	152 ~+		24.41	30	123
<u>Larynx</u> Male	10.47	14	134	<u>Testis</u> Male	8.64	9	104
	2.98		NC*	Male	0.04	9	104
Female		4					
Total	13.46	18	134	Thomasal			
<u>Leukemia</u>	45.00	47	444	<u>Thyroid</u>	4.40	0	NO*
Male	15.36	17	111	Male	4.46	2	NC*
Female	13.97	23	165 #+	Female	13.35	11	82
Total	29.34	40	136	Total	17.80	13	73
Liver and Intrahepa		40	470	Uteri, Corpus and U	terus, NOS		
Male	7.25	13	179				
Female	3.74	5	134	Female	41.82	37	88
Total	10.99	18	164				
Lung and Bronchu				All Sites / Types			
Male	101.34	129	127 ~+	Male	652.00	702	108
Female	93.24	93	100	Female	719.81	721	100
Total	194.58	222	114	Total	1371.82	1423	104

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Manchester
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.16	3	NC*	Male	2.71	6	221
Female	1.60	1	NC*	Female	2.10	5	238
Total	5.77	4	NC*	Total	4.81	11	229 #+
Brain and Other Ce				Multiple Myeloma			
Male	1.17	2	NC*	Male	0.82	0	NC*
Female	0.98	0	NC*	Female	0.74	2	NC*
Total	2.15	2	NC*	Total	1.55	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.20	0	NC*	Male	3.25	3	NC*
Female	26.27	29	110	Female	3.03	1	NC*
Total	26.47	29	110	Total	6.28	4	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	2.60	1	NC*
Female	1.39	0	NC*	Female	1.29	1	NC*
				Total	3.89	2	NC*
Colon / Rectum				<u>Ovary</u>			
Male	10.34	12	116				
Female	10.02	12	120	Female	3.02	3	NC*
Total	20.36	24	118				
Esophagus				<u>Pancreas</u>			
Male	1.51	1	NC*	Male	1.75	2	NC*
Female	0.49	0	NC*	Female	1.86	4	NC*
Total	2.00	1	NC*	Total	3.61	6	166
Hodgkin's Disease	(Hodgkin Lymp	homa)		Prostate			
Male	0.54	0	NC*	Male	26.17	33	126
Female	0.43	0	NC*				
Total	0.97	0	NC*				
Kidney and Renal P	<u>Pelvis</u>			Stomach			
Male	2.44	2	NC*	Male	1.75	1	NC*
Female	1.57	2	NC*	Female	1.08	1	NC*
Total	4.02	4	NC*	Total	2.83	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.42	2	NC*	Male	0.76	1	NC*
Female	0.37	0	NC*				
Total	1.79	2	NC*				
<u>Leukemia</u>				Thyroid			
Male	1.89	1	NC*	Male	0.51	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	1.51	2	NC*	Female	1.37	1	NC*
Total	3.40	3	NC*	Total	1.88	1	NC*
Liver and Intrahep	atic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	0.95	0	NC*				
Female	0.41	0	NC*	Female	5.17	4	NC*
Total	1.36	0	NC*				
Lung and Bronchu	<u>IS</u>			All Sites / Types			
Male	13.25	12	91	Male	83.68	88	105
Female	10.91	10	92	Female	81.41	82	101
Total	24.16	22	91	Total	165.09	170	103

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Mansfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	8.17	8	98	Male	6.64	9	136
Female	2.88	4	NC*	Female	5.23	7	134
Total	11.05	12	109	Total	11.87	16	135
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	3.29	4	NC*	Male	1.71	3	NC*
Female	2.54	2	NC*	Female	1.40	4	NC*
Total	5.83	6	103	Total	3.11	7	225
<u>Breast</u>				Non-Hodgkin('s) Lyr	mphoma		
Male	0.42	1	NC*	Male	7.93	9	114
Female	58.23	62	106	Female	6.35	2	NC*
Total	58.65	63	107	Total	14.28	11	77
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	6.23	6	96
Female	3.94	4	NC*	Female	2.71	2	NC*
				Total	8.93	8	90
Colon / Rectum				<u>Ovary</u>			
Male	20.65	20	97				
Female	18.07	25	138	Female	7.00	10	143
Total	38.72	45	116				
Esophagus				<u>Pancreas</u>			
Male	3.27	3	NC*	Male	3.64	1	NC*
Female	0.86	1	NC*	Female	3.32	3	NC*
Total	4.14	4	NC*	Total	6.96	4	NC*
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	1.89	2	NC*	Male	53.23	36	68 #-
Female	1.45	2	NC*				

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	3.34	4	NC*				
Kidney and Renal P	<u>Pelvis</u>			Stomach			
Male	5.63	5	89	Male	3.62	2	NC*
Female	3.25	5	154	Female	1.97	2	NC*
Total	8.88	10	113	Total	5.59	4	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	3.17	2	NC*	Male	3.10	8	258 #+
Female	0.76	2	NC*				
Total	3.93	4	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	4.62	2	NC*	Male	1.56	1	NC*
Female	3.48	3	NC*	Female	4.26	4	NC*
Total	8.10	5	62	Total	5.82	5	86
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and L	Iterus, NOS		
Male	2.16	0	NC*				
Female	0.77	0	NC*	Female	10.97	13	119
Total	2.93	0	NC*				
Lung and Bronchus	<u>8</u>			All Sites / Types			
Male	27.01	28	104	Male	180.43	164	91
Female	21.27	27	127	Female	172.36	195	113
Total	48.28	55	114	Total	352.80	359	102

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

Marblehead
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	16.37	7	43 #-	Male	10.58	26	246 ^+
Female	6.19	8	129	Female	8.06	14	174
Total	22.55	15	67	Total	18.64	40	215 ^+
Brain and Other Ce	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	4.56	5	110	Male	3.21	2	NC*
Female	3.71	5	135	Female	2.81	2	NC*
Total	8.27	10	121	Total	6.02	4	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.77	0	NC*	Male	12.69	11	87
Female	100.24	126	126 #+	Female	11.60	11	95
Total	101.01	126	125 #+	Total	24.29	22	91
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	10.21	8	78
Female	5.31	6	113	Female	4.95	4	NC*
				Total	15.16	12	79

^{* =} SIR and statistical significance not calculated when **Obs** < 5

 $[\]land$ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Colon / Rectum				<u>Ovary</u>			
Male	40.60	28	69 #-				
Female	38.70	42	109	Female	11.50	18	156
Total	79.30	70	88				
Esophagus				<u>Pancreas</u>			
Male	5.94	2	NC*	Male	6.91	8	116
Female	1.89	4	NC*	Female	7.14	10	140
Total	7.83	6	77	Total	14.05	18	128
Hodgkin's Disease	(Hodgkin Lympl	noma)		Prostate			
Male	2.05	3	NC*	Male	102.82	152	148 ^+
Female	1.65	1	NC*				
Total	3.70	4	NC*				
Kidney and Renal P	<u>Pelvis</u>			Stomach			
Male	9.57	10	105	Male	6.91	9	130
Female	6.00	3	NC*	Female	4.18	3	NC*
Total	15.56	13	84	Total	11.09	12	108
<u>Larynx</u>				<u>Testis</u>			
Male	5.56	6	108	Male	2.81	7	249
Female	1.41	0	NC*				
Total	6.97	6	86				
<u>Leukemia</u>				Thyroid			
Male	7.36	13	177	Male	1.98	4	NC*
Female	5.82	9	155	Female	5.24	7	133
Total	13.19	22	167 #+	Total	7.22	11	152
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and L	<u>Jterus, NOS</u>		
Male	3.73	0	NC*				
Female	1.56	0	NC*	Female	19.63	19	97
Total	5.29	0	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	51.92	33	64 ~-	Male	328.06	353	108
Female	41.37	32	77	Female	311.38	345	111
Total	93.29	65	70 ~-	Total	639.44	698	109 #+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Marion

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	4.17	5	120	Male	2.82	8	284 #+
Female	1.36	2	NC*	Female	1.99	1	NC*
Total	5.53	7	127	Total	4.81	9	187
Brain and Other C	entral Nervous S	<u>ystem</u>		Multiple Myeloma			

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	1.26	0	NC*	Male	0.84	0	NC*
Female	0.96	0	NC*	Female	0.67	1	NC*
Total	2.22	0	NC*	Total	1.52	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	0.20	1	NC*	Male	3.35	1	NC*
Female	25.32	24	95	Female	2.77	2	NC*
Total	25.52	25	98	Total	6.13	3	NC*
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	2.76	2	NC*
Female	1.35	1	NC*	Female	1.21	0	NC*
				Total	3.97	2	NC*
Colon / Rectum				<u>Ovary</u>			
Male	10.41	8	77				
Female	8.48	4	NC*	Female	2.92	3	NC*
Total	18.89	12	64				
Esophagus				<u>Pancreas</u>			
Male	1.58	1	NC*	Male	1.79	1	NC*
Female	0.41	0	NC*	Female	1.61	1	NC*
Total	1.99	1	NC*	Total	3.39	2	NC*
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	0.56	0	NC*	Male	27.16	29	107
Female	0.41	0	NC*				
Total	0.97	0	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	2.58	2	NC*	Male	1.76	2	NC*
Female	1.49	1	NC*	Female	0.88	0	NC*
Total	4.06	3	NC*	Total	2.64	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.50	0	NC*	Male	0.76	1	NC*
Female	0.37	0	NC*				
Total	1.87	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.97	1	NC*	Male	0.54	0	NC*
Female	1.37	3	NC*	Female	1.34	0	NC*
Total	3.33	4	NC*	Total	1.88	0	NC*
Liver and Intrahepa				Uteri, Corpus and L	Iterus, NOS		
Male	1.00	0	NC*				
Female	0.36	0	NC*	Female	5.08	5	98
Total	1.36	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	13.65	8	59	Male	86.25	73	85
Female	10.48	8	76	Female	75.83	59	78
Total	24.13	16	66	Total	162.08	132	81 #-

Obs = observed case count

 $^{^*}$ = SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $p \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $p \leq$ 0.01 level, as well as at the $p \leq$ 0.05 level

Marlborough
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

Dladday Hrinam	<u>Exp</u>	<u>Obs</u>	SIR	Malanama of Skin	<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary	16.60	15	00	Melanoma of Skin	10.55	0	70
Male	16.68	15	90	Male	12.55	9	72 50
Female	7.14	5	70	Female	10.23	6	59 66
Total	23.81	20	84	Total	22.78	15	66
Brain and Other Ce		-	NC*	Multiple Myeloma	2.26	0	000 #
Male Female	5.96 4.83	4 3	NC* NC*	Male Female	3.36 3.19	8 2	238 #+ NC*
Total	10.79	7	65	Total	6.54	10	153
Breast Male	0.82	1	NC*	Non-Hodgkin('s) Ly Male	<u>mpnoma</u> 15.09	17	113
Female	116.83	130	111	Female	13.91	13	93
Total	117.64	131	111	Total	29.00	30	103
Cervix Uteri				Oral Cavity and Pha		45	101
Famala	7.00	0	02	Male	11.42	15	131
Female	7.23	6	83	Female	5.75	5	87
0.1/ 0(Total	17.17	20	116
Colon / Rectum	44.04	40	100	<u>Ovary</u>			
Male	41.91	43	103	F I.	40.00	7	5 4
Female	44.79	43	96	Female	13.82	7	51
Total	86.70	86	99	_			
<u>Esophagus</u>	0.05	_	22	<u>Pancreas</u>	7.40	_	00
Male	6.25	5	80	Male	7.16	7	98
Female	2.17	1	NC*	Female	8.21	9	110
Total	8.42	6	71	Total	15.37	16	104
Hodgkin's Disease				<u>Prostate</u>			
Male	3.45	5	145	Male	105.59	107	101
Female	2.60	3	NC*				
Total	6.06	8	132				
Kidney and Renal P				<u>Stomach</u>			
Male	10.64	13	122	Male	7.15	9	126
Female	6.95	2	NC*	Female	4.93	4	NC*
Total	17.59	15	85	Total	12.09	13	108
<u>Larynx</u>				<u>Testis</u>			
Male	5.97	5	84	Male	5.81	7	121
Female	1.56	0	NC*				
Total	7.54	5	66				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.70	12	138	Male	2.84	4	NC*
Female	7.26	11	151	Female	7.58	4	NC*
Total	15.96	23	144	Total	10.42	8	77
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	<u>lterus, NOS</u>		
Male	4.10	6	146				
Female	1.81	5	277	Female	22.05	13	59
Total	5.91	11	186				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	54.14	63	116	Male	354.06	372	105
Female	46.66	57	122	Female	366.25	367	100

Total 100.80 120 119 Total 720.31 739 103

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Marshfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	11.31	9	80	Male	8.78	8	91
Female	4.26	6	141	Female	6.91	5	72
Total	15.57	15	96	Total	15.69	13	83
Brain and Other C	entral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	4.19	4	NC*	Male	2.36	4	NC*
Female	3.30	3	NC*	Female	2.07	2	NC*
Total	7.49	7	93	Total	4.43	6	135
<u>Breast</u>				Non-Hodgkin('s) Lyr	mphoma		
Male	0.57	0	NC*	Male	10.39	7	67
Female	81.96	80	98	Female	8.92	9	101
Total	82.53	80	97	Total	19.32	16	83
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	8.48	8	94
Female	4.95	4	NC*	Female	3.86	8	207
				Total	12.34	16	130
Colon / Rectum				<u>Ovary</u>			
Male	28.65	25	87				
Female	26.60	32	120	Female	9.63	16	166
Total	55.25	57	103				
Esophagus				<u>Pancreas</u>			
Male	4.58	12	262 ~+	Male	5.05	7	139
Female	1.29	0	NC*	Female	4.95	2	NC*
Total	5.86	12	205 #+	Total	10.00	9	90
Hodgkin's Disease	e (Hodgkin Lymp	<u>homa)</u>		Prostate			
Male	2.22	4	NC*	Male	76.31	81	106
Female	1.67	1	NC*				
Total	3.89	5	128				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	7.66	8	104	Male	4.96	2	NC*
Female	4.68	7	150	Female	2.85	1	NC*
Total	12.33	15	122	Total	7.81	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	4.43	4	NC*	Male	3.47	4	NC*
Female	1.13	2	NC*				
Total	5.56	6	108				

^{* =} SIR and statistical significance not calculated when **Obs** < 5

<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.99	6	100	Male	1.96	4	NC*
Female	4.68	5	107	Female	5.15	6	117
Total	10.67	11	103	Total	7.10	10	141
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	2.97	1	NC*				
Female	1.12	1	NC*	Female	15.89	15	94
Total	4.09	2	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	38.06	62	163 ^+	Male	248.90	281	113 #+
Female	31.57	41	130	Female	243.84	265	109
Total	69.63	103	148 ^+	Total	492.75	546	111 #+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Mashpee
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	7.03	13	185	Male	4.27	8	187
Female	2.49	2	NC*	Female	3.23	4	NC*
Total	9.52	15	158	Total	7.50	12	160
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.87	5	267	Male	1.32	1	NC*
Female	1.56	2	NC*	Female	1.09	0	NC*
Total	3.43	7	204	Total	2.41	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym			
Male	0.31	2	NC*	Male	5.28	7	133
Female	37.97	54	142 #+	Female	4.69	2	NC*
Total	38.28	56	146 ~+	Total	9.96	9	90
Cervix Uteri				Oral Cavity and Phary	<u>/nx</u>		
				Male	3.90	8	205
Female	2.19	3	NC*	Female	1.91	4	NC*
				Total	5.82	12	206 #+
Colon / Rectum				<u>Ovary</u>			
Male	17.27	26	151				
Female	15.61	19	122	Female	4.45	4	NC*
Total	32.88	45	137				
Esophagus				<u>Pancreas</u>			
Male	2.34	1	NC*	Male	2.85	4	NC*
Female	0.76	4	NC*	Female	2.88	7	243
Total	3.11	5	161	Total	5.73	11	192
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	0.91	0	NC*	Male	41.29	81	196 ^+
Female	0.78	0	NC*				
Total	1.69	0	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	3.80	4	NC*	Male	2.91	7	241
Female	2.34	3	NC*	Female	1.71	2	NC*
Total	6.14	7	114	Total	4.62	9	195
<u>Larynx</u>				<u>Testis</u>			
Male	2.14	0	NC*	Male	1.32	3	NC*
Female	0.53	0	NC*				
Total	2.67	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.16	3	NC*	Male	0.78	2	NC*
Female	2.41	1	NC*	Female	2.25	2	NC*
Total	5.57	4	NC*	Total	3.03	4	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	1.48	4	NC*				
Female	0.63	1	NC*	Female	7.27	8	110
Total	2.10	5	238				
Lung and Bronchus	<u> </u>			All Sites / Types			
Male	21.34	30	141	Male	134.83	228	169 ^+
Female	16.06	28	174 ~+	Female	121.88	160	131 ~+
Total	37.40	58	155 ~+	Total	256.70	388	151 ^+

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Mattapoisett
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.91	4	NC*	Male	3.13	3	NC*
Female	1.87	2	NC*	Female	2.35	5	213
Total	6.78	6	88	Total	5.48	8	146
Brain and Other Cen	itral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.34	1	NC*	Male	0.95	3	NC*
Female	1.10	0	NC*	Female	0.85	0	NC*
Total	2.45	1	NC*	Total	1.80	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.23	0	NC*	Male	3.77	0	NC*
Female	29.51	31	105	Female	3.48	4	NC*
Total	29.74	31	104	Total	7.25	4	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	3.01	3	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	1.52	2	NC*	Female	1.47	0	NC*
				Total	4.48	3	NC*
Colon / Rectum				<u>Ovary</u>			
Male	12.15	15	123				
Female	11.72	8	68	Female	3.38	2	NC*
Total	23.87	23	96				
Esophagus Page 1				<u>Pancreas</u>			
Male	1.76	1	NC*	Male	2.06	3	NC*
Female	0.57	0	NC*	Female	2.17	2	NC*
Total	2.34	1	NC*	Total	4.23	5	118
Hodgkin's Disease	(Hodgkin Lympl	noma)		<u>Prostate</u>			
Male	0.60	0	NC*	Male	30.52	33	108
Female	0.47	0	NC*				
Total	1.08	0	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	2.82	3	NC*	Male	2.07	2	NC*
Female	1.80	2	NC*	Female	1.26	2	NC*
Total	4.62	5	108	Total	3.33	4	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.64	2	NC*	Male	0.83	1	NC*
Female	0.42	0	NC*				
Total	2.06	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.19	1	NC*	Male	0.58	0	NC*
Female	1.74	2	NC*	Female	1.49	1	NC*
Total	3.92	3	NC*	Total	2.07	1	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.10	1	NC*				
Female	0.47	0	NC*	Female	5.82	7	120
Total	1.57	1	NC*				
Lung and Bronchus	<u>8</u>			All Sites / Types			
Male	15.42	11	71	Male	97.53	93	95
Female	12.53	18	144	Female	92.71	98	106
Total	27.96	29	104	Total	190.24	191	100

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Maynard
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	6.06	6	99	Male	4.30	1	NC*
Female	2.75	0	NC*	Female	3.63	5	138

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	8.81	6	68	Total	7.93	6	76
Brain and Other Ce		ystem		Multiple Myeloma			
Male	1.97	4	NC*	Male	1.21	0	NC*
Female	1.72	2	NC*	Female	1.24	1	NC*
Total	3.69	6	163	Total	2.45	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	0.29	1	NC*	Male	5.16	5	97
Female	43.28	43	99	Female	5.23	8	153
Total	43.58	44	101	Total	10.39	13	125
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	4.04	3	NC*
Female	2.45	6	245	Female	2.15	0	NC*
				Total	6.19	3	NC*
Colon / Rectum				<u>Ovary</u>			
Male	15.16	15	99				
Female	17.32	22	127	Female	5.05	5	99
Total	32.48	37	114				
Esophagus				<u>Pancreas</u>			
Male	2.26	4	NC*	Male	2.59	2	NC*
Female	0.84	0	NC*	Female	3.17	2	NC*
Total	3.10	4	NC*	Total	5.77	4	NC*
Hodgkin's Disease	(Hodgkin Lympl	<u>homa)</u>		<u>Prostate</u>			
Male	1.04	3	NC*	Male	38.42	38	99
Female	0.84	1	NC*				
Total	1.87	4	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	3.75	3	NC*	Male	2.59	3	NC*
Female	2.63	3	NC*	Female	1.87	1	NC*
Total	6.38	6	94	Total	4.46	4	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.14	1	NC*	Male	1.63	1	NC*
Female	0.60	0	NC*				
Total	2.74	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.98	2	NC*	Male	0.91	1	NC*
Female	2.62	3	NC*	Female	2.50	5	200
Total	5.60	5	89	Total	3.40	6	176
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	1.45	2	NC*				
Female	0.69	0	NC*	Female	8.35	10	120
Total	2.15	2	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	19.53	30	154 #+	Male	126.00	132	105
Female	18.14	13	72	Female	137.08	137	100
Total	37.66	43	114	Total	263.08	269	102

Obs = observed case count

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

- \thicksim indicates statistical significance at the $p \leq$ 0.01 level, as well as at the $p \leq$ 0.05 level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

MedfieldExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	6.48	4	NC*	Male	4.91	6	122
Female	2.22	1	NC*	Female	3.59	6	167
Total	8.69	5	58	Total	8.49	12	141
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	2.32	5	215	Male	1.36	2	NC*
Female	1.72	3	NC*	Female	1.09	0	NC*
Total	4.04	8	198	Total	2.45	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	<u>nphoma</u>		
Male	0.33	0	NC*	Male	5.78	8	138
Female	43.36	45	104	Female	4.63	4	NC*
Total	43.69	45	103	Total	10.41	12	115
Cervix Uteri				Oral Cavity and Phar	rynx		
				Male	4.84	3	NC*
Female	2.54	0	NC*	Female	2.04	2	NC*
				Total	6.88	5	73
Colon / Rectum				<u>Ovary</u>			
Male	16.43	8	49 #-				
Female	13.77	10	73	Female	5.07	1	NC*
Total	30.21	18	60 #-				
Esophagus				<u>Pancreas</u>			
Male	2.64	3	NC*	Male	2.89	3	NC*
Female	0.67	0	NC*	Female	2.58	1	NC*
Total	3.31	3	NC*	Total	5.47	4	NC*
Hodgkin's Disease	(Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	1.14	0	NC*	Male	44.75	40	89
Female	0.83	0	NC*				
Total	1.97	0	NC*				
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>			
Male	4.40	5	114	Male	2.81	2	NC*
Female	2.46	1	NC*	Female	1.48	0	NC*
Total	6.86	6	87	Total	4.29	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.57	3	NC*	Male	1.67	0	NC*
Female	0.60	0	NC*				
Total	3.18	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.36	7	208	Male	1.05	1	NC*
Female	2.46	2	NC*	Female	2.62	4	NC*
Total	5.82	9	155	Total	3.66	5	136
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and Ut	terus, NOS		
Male	1.70	1	NC*				
Female	0.59	1	NC*	Female	8.47	10	118
Total	2.29	2	NC*				
Lung and Bronchus	<u> </u>			All Sites / Types			

Male	22.17	16	72	Male	142.86	123	86
Female	16.59	16	96	Female	127.90	114	89
Total	38.77	32	83	Total	270.76	237	88 #-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- \land indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels

Medford
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	•		•		,		
	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	38.46	24	62 #-	Male	24.75	22	89
Female	17.03	18	106	Female	21.36	13	61
Total	55.49	42	76	Total	46.10	35	76
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	10.89	13	119	Male	7.32	10	137
Female	10.00	10	100	Female	7.44	9	121
Total	20.89	23	110	Total	14.77	19	129
<u>Breast</u>				Non-Hodgkin('s) Lyı	mphoma		
Male	1.76	2	NC*	Male	30.22	27	89
Female	252.03	265	105	Female	31.60	53	168 ^+
Total	253.79	267	105	Total	61.82	80	129 #+
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	22.39	15	67
Female	14.37	14	97	Female	12.77	15	117
				Total	35.16	30	85
Colon / Rectum				<u>Ovary</u>			
Male	95.03	104	109				
Female	107.30	102	95	Female	29.44	30	102
Total	202.34	206	102				
Esophagus				<u>Pancreas</u>			
Male	13.14	11	84	Male	15.77	15	95
Female	5.23	6	115	Female	19.67	16	81
Total	18.36	17	93	Total	35.44	31	87
Hodgkin's Disease	(Hodgkin Lymp	ohoma)		<u>Prostate</u>			
Male	5.68	4	NC*	Male	230.06	216	94
Female	5.01	6	120				
Total	10.69	10	94				
Kidney and Renal F	<u>Pelvis</u>			<u>Stomach</u>			
Male	21.60	20	93	Male	15.98	25	156 #+
Female	15.64	18	115	Female	11.67	18	154
Total	37.24	38	102	Total	27.64	43	156 ~+
<u>Larynx</u>				<u>Testis</u>			
Male	12.17	7	58	Male	8.97	12	134

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	3.49	7	201				
Total	15.66	14	89				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	17.62	17	96	Male	4.86	4	NC*
Female	15.55	17	109	Female	14.63	18	123
Total	33.17	34	103	Total	19.48	22	113
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	<u> Jterus, NOS</u>		
Male	8.38	7	84				
Female	4.23	4	NC*	Female	48.24	53	110
Total	12.61	11	87				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	118.99	130	109	Male	755.87	744	98
Female	108.58	130	120 #+	Female	816.42	886	109 #+
Total	227.57	260	114 #+	Total	1572.30	1630	104

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

MedwayExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR	
Bladder, Urinary	 _	<u> </u>		Melanoma of Skin	 -		<u> </u>	
Male	5.70	13	228 #+	Male	4.32	7	162	
Female	2.09	3	NC*	Female	3.36	5	149	
Total	7.79	16	205 #+	Total	7.68	12	156	
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma				
Male	2.07	0	NC*	Male	1.18	0	NC*	
Female	1.61	4	NC*	Female	0.99	0	NC*	
Total	3.68	4	NC*	Total	2.17	0	NC*	
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>			
Male	0.29	0	NC*	Male	5.14	8	156	
Female	39.40	38	96	Female	4.31	10	232 #+	
Total	39.69	38	96	Total	9.44	18	191 #+	
Cervix Uteri				Oral Cavity and Pharynx				
				Male	4.15	2	NC*	
Female	2.41	1	NC*	Female	1.87	2	NC*	
				Total	6.03	4	NC*	
Colon / Rectum				<u>Ovary</u>				
Male	14.40	14	97					
Female	12.99	10	77	Female	4.64	4	NC*	
Total	27.38	24	88					
Esophagus				<u>Pancreas</u>				
Male	2.26	2	NC*	Male	2.52	2	NC*	
Female	0.63	0	NC*	Female	2.42	1	NC*	

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	2.89	2	NC*	Total	4.94	3	NC*
Hodgkin's Disease	(Hodgkin Lymph	noma <u>)</u>		<u>Prostate</u>			
Male	1.08	2	NC*	Male	37.97	39	103
Female	0.83	0	NC*				
Total	1.91	2	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	3.79	3	NC*	Male	2.48	3	NC*
Female	2.25	2	NC*	Female	1.42	0	NC*
Total	6.05	5	83	Total	3.90	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.18	3	NC*	Male	1.65	4	NC*
Female	0.54	0	NC*				
Total	2.72	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.01	3	NC*	Male	0.94	1	NC*
Female	2.35	1	NC*	Female	2.51	3	NC*
Total	5.35	4	NC*	Total	3.46	4	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.47	0	NC*				
Female	0.55	0	NC*	Female	7.57	4	NC*
Total	2.02	0	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	19.04	15	79	Male	123.87	132	107
Female	14.93	12	80	Female	117.78	109	93
Total	33.97	27	79	Total	241.65	241	100

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Melrose
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	19.07	12	63	Male	12.07	13	108
Female	8.60	9	105	Female	10.20	12	118
Total	27.67	21	76	Total	22.26	25	112
Brain and Other Ce	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	5.19	7	135	Male	3.64	3	NC*
Female	4.71	8	170	Female	3.71	1	NC*
Total	9.90	15	151	Total	7.36	4	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	<u>nphoma</u>		
Male	0.87	0	NC*	Male	14.67	15	102
Female	123.96	134	108	Female	15.41	10	65
Total	124.84	134	107	Total	30.08	25	83

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	11.24	9	80
Female	6.56	7	107	Female	6.34	7	110
				Total	17.59	16	91
Colon / Rectum				<u>Ovary</u>			
Male	46.99	43	92				
Female	54.07	62	115	Female	14.27	19	133
Total	101.06	105	104				
Esophagus				<u>Pancreas</u>			
Male	6.61	2	NC*	Male	7.88	14	178
Female	2.64	5	190	Female	9.87	10	101
Total	9.24	7	76	Total	17.75	24	135
Hodgkin's Disease	(Hodgkin Lymp	homa <u>)</u>		Prostate			
Male	2.51	2	NC*	Male	114.17	156	137 ^+
Female	2.17	1	NC*				
Total	4.67	3	NC*				
Kidney and Renal	<u>Pelvis</u>			Stomach .			
Male	10.69	14	131	Male	8.00	7	87
Female	7.70	11	143	Female	5.92	2	NC*
Total	18.40	25	136	Total	13.92	9	65
<u>Larynx</u>				<u>Testis</u>			
Male	6.09	6	98	Male	3.68	8	217
Female	1.72	1	NC*				
Total	7.81	7	90				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.54	10	117	Male	2.27	5	220
Female	7.73	7	91	Female	6.50	9	139
Total	16.28	17	104	Total	8.77	14	160
Liver and Intrahep	atic Bile Ducts			Uteri, Corpus and L	<u>Iterus, NOS</u>		
Male	4.16	3	NC*				
Female	2.12	4	NC*	Female	23.91	26	109
Total	6.27	7	112				
Lung and Bronchu	<u>IS</u>			All Sites / Types			
Male	58.61	43	73 #-	Male	372.18	389	105
Female	53.14	44	83	Female	401.94	404	101
Total	111.75	87	78 #-	Total	774.11	793	102

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Mendon

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Bladder, Urinary</u> <u>Melanoma of Skin</u>

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	2.56	4	NC*	Male	1.95	0	NC*
Female	0.92	0	NC*	Female	1.45	0	NC*
Total	3.47	4	NC*	Total	3.40	0	NC*
Brain and Other Ce	entral Nervous Sy	<u>ystem</u>		Multiple Myeloma			
Male	0.91	0	NC*	Male	0.53	1	NC*
Female	0.69	0	NC*	Female	0.44	2	NC*
Total	1.60	0	NC*	Total	0.97	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	0.13	0	NC*	Male	2.30	2	NC*
Female	17.20	22	128	Female	1.88	3	NC*
Total	17.33	22	127	Total	4.18	5	120
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	1.91	0	NC*
Female	1.04	0	NC*	Female	0.82	0	NC*
				Total	2.72	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	6.46	9	139				
Female	5.72	4	NC*	Female	2.02	4	NC*
Total	12.17	13	107				
Esophagus				<u>Pancreas</u>			
Male	1.03	1	NC*	Male	1.14	3	NC*
Female	0.28	0	NC*	Female	1.06	1	NC*
Total	1.31	1	NC*	Total	2.20	4	NC*
Hodgkin's Disease	(Hodgkin Lymph	noma)		<u>Prostate</u>			
Male	0.46	0	NC*	Male	17.17	8	47 #-
Female	0.35	2	NC*				
Total	0.81	2	NC*				
Kidney and Renal F	<u>Pelvis</u>			<u>Stomach</u>			
Male	1.72	0	NC*	Male	1.12	1	NC*
Female	0.98	0	NC*	Female	0.62	1	NC*
Total	2.70	0	NC*	Total	1.74	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.00	0	NC*	Male	0.70	0	NC*
Female	0.23	1	NC*				
Total	1.23	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.32	0	NC*	Male	0.42	1	NC*
Female	0.99	0	NC*	Female	1.07	2	NC*
Total	2.32	0	NC*	Total	1.50	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	0.67	0	NC*				
Female	0.24	2	NC*	Female	3.32	4	NC*
Total	0.90	2	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	8.57	4	NC*	Male	55.74	36	65 ~-
Female	6.60	6	91	Female	51.43	59	115
Total	15.17	10	66	Total	107.17	95	89

Obs = observed case count

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Merrimac
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.52	5	142	Male	2.54	1	NC*
Female	1.35	0	NC*	Female	1.99	2	NC*
Total	4.87	5	103	Total	4.53	3	NC*
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	1.18	0	NC*	Male	0.72	2	NC*
Female	0.94	1	NC*	Female	0.63	1	NC*
Total	2.12	1	NC*	Total	1.34	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.17	0	NC*	Male	3.03	1	NC*
Female	23.69	19	80	Female	2.68	2	NC*
Total	23.86	19	80	Total	5.71	3	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	2.44	0	NC*
Female	1.39	1	NC*	Female	1.14	0	NC*
				Total	3.59	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	8.84	8	91				
Female	8.42	10	119	Female	2.77	5	181
Total	17.25	18	104				
Esophagus Page 1				<u>Pancreas</u>			
Male	1.36	0	NC*	Male	1.53	1	NC*
Female	0.41	1	NC*	Female	1.56	2	NC*
Total	1.77	1	NC*	Total	3.09	3	NC*
Hodgkin's Disease		<u>homa)</u>		<u>Prostate</u>			
Male	0.59	1	NC*	Male	22.93	18	79
Female	0.47	1	NC*				
Total	1.06	2	NC*				
Kidney and Renal P				<u>Stomach</u>			
Male	2.25	4	NC*	Male	1.52	2	NC*
Female	1.38	2	NC*	Female	0.91	0	NC*
Total	3.63	6	165	Total	2.43	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.30	2	NC*	Male	0.89	1	NC*
Female	0.33	0	NC*				
Total	1.62	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.77	1	NC*	Male -	0.53	1	NC*
Female	1.40	1	NC*	Female	1.43	2	NC*
Total	3.17	2	NC*	Total	1.96	3	NC*
Liver and Intrahepa		_	NOT	Uteri, Corpus and Ut	erus, NOS		
Male	0.87	2	NC*		4	_	
Female	0.35	0	NC*	Female	4.58	7	153

Total	1.22	2	NC*				
Lung and Bronchus	<u>i</u>			All Sites / Types			
Male	11.54	8	69	Male	74.46	61	82
Female	9.36	13	139	Female	72.23	74	102
Total	20.90	21	100	Total	146.69	135	92

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** < 0.001 level, as well as at the **p** < 0.05 and **p** < 0.01 levels

Methuen

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

			,				
	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	27.99	28	100	Male	18.08	9	50 #-
Female	12.21	12	98	Female	14.72	13	88
Total	40.20	40	99	Total	32.80	22	67
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	8.07	10	124	Male	5.39	9	167
Female	7.06	11	156	Female	5.35	6	112
Total	15.13	21	139	Total	10.74	15	140
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	1.29	1	NC*	Male	22.04	23	104
Female	178.75	187	105	Female	22.33	24	107
Total	180.05	188	104	Total	44.37	47	106
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	16.71	8	48 #-
Female	9.53	10	105	Female	9.11	9	99
				Total	25.83	17	66
Colon / Rectum				<u>Ovary</u>			
Male	69.16	84	121				
Female	76.87	63	82	Female	20.71	20	97
Total	146.03	147	101				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	9.73	15	154	Male	11.56	7	61
Female	3.75	6	160	Female	14.08	17	121
Total	13.48	21	156	Total	25.64	24	94
Hodgkin's Disease	(Hodgkin Lymp	homa <u>)</u>		Prostate			
Male	4.01	9	224 #+	Male	168.85	198	117 #+
Female	3.25	4	NC*				
Total	7.26	13	179				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	16.02	18	112	Male	11.69	21	180 #+
Female	11.17	12	107	Female	8.32	14	168
Total	27.19	30	110	Total	20.02	35	175 ~+

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

<u>Larynx</u>				<u>Testis</u>			
Male	9.05	9	99	Male	6.01	7	117
Female	2.51	4	NC*				
Total	11.56	13	112				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	13.06	11	84	Male	3.49	3	NC*
Female	11.24	12	107	Female	9.52	9	95
Total	24.30	23	95	Total	13.01	12	92
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	Iterus, NOS		
Male	6.20	3	NC*				
Female	3.04	2	NC*	Female	34.66	43	124
Total	9.24	5	54				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	87.00	84	97	Male	553.17	582	105
Female	77.64	82	106	Female	579.55	601	104
Total	164.63	166	101	Total	1132.71	1183	104

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

MiddleboroughExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	9.83	12	122	Male	7.36	2	NC*
Female	4.04	1	NC*	Female	6.06	3	NC*
Total	13.88	13	94	Total	13.42	5	37 #-
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	3.49	5	143	Male	2.01	1	NC*
Female	2.87	4	NC*	Female	1.85	4	NC*
Total	6.36	9	142	Total	3.87	5	129
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	0.49	1	NC*	Male	8.79	10	114
Female	70.09	70	100	Female	8.04	8	99
Total	70.58	71	101	Total	16.83	18	107
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	7.01	4	NC*
Female	4.30	4	NC*	Female	3.39	1	NC*
				Total	10.40	5	48
Colon / Rectum				<u>Ovary</u>			
Male	24.70	25	101				
Female	25.38	27	106	Female	8.26	8	97
Total	50.08	52	104				
Esophagus				<u>Pancreas</u>			

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	3.82	4	NC*	Male	4.30	7	163
Female	1.23	0	NC*	Female	4.64	5	108
Total	5.04	4	NC*	Total	8.94	12	134
Hodgkin's Diseas	<u>e (Hodgkin Lymph</u>	<u>noma)</u>		<u>Prostate</u>			
Male	1.85	2	NC*	Male	63.55	65	102
Female	1.51	2	NC*				
Total	3.36	4	NC*				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	6.42	5	78	Male	4.27	3	NC*
Female	4.08	4	NC*	Female	2.78	2	NC*
Total	10.50	9	86	Total	7.06	5	71
<u>Larynx</u>				<u>Testis</u>			
Male	3.66	5	137	Male	2.87	3	NC*
Female	0.93	1	NC*				
Total	4.59	6	131				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	5.13	10	195	Male	1.60	6	375 #+
Female	4.26	7	164	Female	4.49	5	111
Total	9.40	17	181 #+	Total	6.09	11	181
Liver and Intraher	patic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	2.48	1	NC*				
Female	1.03	1	NC*	Female	13.32	9	68
Total	3.51	2	NC*				
Lung and Bronch	<u>us</u>			All Sites / Types			
Male	32.16	46	143 #+	Male	209.97	230	110
Female	27.21	22	81	Female	215.22	200	93
Total	59.37	68	115	Total	425.19	430	101

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Middlefield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.28	0	NC*	Male	0.21	0	NC*
Female	0.09	0	NC*	Female	0.13	0	NC*
Total	0.37	0	NC*	Total	0.33	0	NC*
Brain and Other Cent	tral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	0.09	0	NC*	Male	0.06	0	NC*
Female	0.06	0	NC*	Female	0.04	0	NC*
Total	0.16	0	NC*	Total	0.10	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>ohoma</u>		
Male	0.01	0	NC*	Male	0.25	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	1.55	0	NC*	Female	0.17	1	NC*
Total	1.56	0	NC*	Total	0.42	1	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	0.20	0	NC*
Female	0.09	0	NC*	Female	0.07	0	NC*
				Total	0.28	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	0.71	0	NC*				
Female	0.53	0	NC*	Female	0.18	0	NC*
Total	1.24	0	NC*				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	0.11	0	NC*	Male	0.12	0	NC*
Female	0.03	0	NC*	Female	0.10	0	NC*
Total	0.14	0	NC*	Total	0.22	0	NC*
Hodgkin's Disease		oma)		<u>Prostate</u>			
Male	0.05	0	NC*	Male	1.80	2	NC*
Female	0.03	0	NC*				
Total	0.08	0	NC*				
Kidney and Renal				<u>Stomach</u>			
Male	0.18	0	NC*	Male	0.12	0	NC*
Female	0.09	0	NC*	Female	0.06	0	NC*
Total	0.28	0	NC*	Total	0.18	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.11	0	NC*	Male	0.07	0	NC*
Female	0.02	0	NC*				
Total	0.13	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.14	0	NC*	Male	0.04	0	NC*
Female	0.09	0	NC*	Female	0.09	1	NC*
Total	0.23	0	NC*	Total	0.13	1	NC*
Liver and Intrahep				Uteri, Corpus and Ut	erus, NOS		
Male	0.07	0	NC*		2.24	•	1104
Female	0.02	0	NC*	Female	0.31	0	NC*
Total	0.09	0	NC*	AH 014 / T			
Lung and Bronchi		•	NO	All Sites / Types	5.00	•	N.0*
Male	0.91	0	NC*	Male	5.96	2	NC*
Female	0.64	0	NC*	Female	4.69	2	NC*
Total	1.55	0	NC*	Total	10.65	4	NC*

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Middleton

^{* =} SIR and statistical significance not calculated when **Obs** < 5

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.93	10	254 #+	Male	2.69	4	NC*
Female	1.30	0	NC*	Female	1.93	0	NC*
Total	5.23	10	191	Total	4.62	4	NC*
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	1.21	2	NC*	Male	0.78	0	NC*
Female	0.92	1	NC*	Female	0.62	0	NC*
Total	2.13	3	NC*	Total	1.40	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyı	mphoma		
Male	0.19	0	NC*	Male	3.23	0	NC*
Female	23.32	26	112	Female	2.62	3	NC*
Total	23.50	26	111	Total	5.85	3	NC*
Cervix Uteri				Oral Cavity and Pha	rynx		
				Male	2.57	3	NC*
Female	1.35	1	NC*	Female	1.12	2	NC*
				Total	3.69	5	136
Colon / Rectum				<u>Ovary</u>			
Male	9.79	8	82	 -			
Female	8.11	6	74	Female	2.72	1	NC*
Total	17.90	14	78				
Esophagus				Pancreas Pancreas			
Male	1.46	0	NC*	Male	1.68	1	NC*
Female	0.39	0	NC*	Female	1.51	2	NC*
Total	1.85	0	NC*	Total	3.18	3	NC*
Hodgkin's Disease (Prostate			
Male	0.59	3	NC*	Male	24.75	16	65
Female	0.45	0	NC*				
Total	1.04	3	NC*				
Kidney and Renal P		·		Stomach			
Male	2.39	1	NC*	Male	1.68	1	NC*
Female	1.36	1	NC*	Female	0.86	1	NC*
Total	3.75	2	NC*	Total	2.54	2	NC*
<u>Larynx</u>	0.70	=		<u>Testis</u>	2.0 .	=	
Male	1.37	2	NC*	Male	0.88	1	NC*
Female	0.33	0	NC*		0.00	·	
Total	1.70	2	NC*				
<u>Leukemia</u>	0	=		<u>Thyroid</u>			
Male	1.88	4	NC*	Male	0.54	1	NC*
Female	1.33	0	NC*	Female	1.38	2	NC*
Total	3.21	4	NC*	Total	1.92	3	NC*
Liver and Intrahepat		7	140	Uteri, Corpus and U		U	110
Male	0.93	0	NC*	oten, corpus una c	<u>terus, 1100</u>		
Female	0.34	0	NC*	Female	4.56	4	NC*
Total	1.26	0	NC*	i citiale	7.00	7	140
Lung and Bronchus		U	110	All Sites / Types			
Male	12.56	12	96	Male	80.45	84	104
Female	9.39	7	90 75	Female	70.72	62	88
Total	21.94	19	87	Total	151.18	146	97
i Ulai	۲۱.۵4	13	O1	IUlai	131.10	140	31

Obs = observed case count

- * = SIR and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Milford
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	15.07	14	93	Male	10.27	11	107
Female	6.31	10	159	Female	8.36	12	144
Total	21.38	24	112	Total	18.63	23	123
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	4.65	4	NC*	Male	2.96	4	NC*
Female	3.99	7	175	Female	2.83	5	177
Total	8.65	11	127	Total	5.78	9	156
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	0.71	1	NC*	Male	12.42	14	113
Female	99.14	101	102	Female	12.01	12	100
Total	99.85	102	102	Total	24.43	26	106
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	9.55	7	73
Female	5.67	2	NC*	Female	4.94	4	NC*
				Total	14.49	11	76
Colon / Rectum				<u>Ovary</u>			
Male	37.42	40	107				
Female	39.73	38	96	Female	11.59	12	104
Total	77.16	78	101				
Esophagus				<u>Pancreas</u>			
Male	5.42	5	92	Male	6.34	10	158
Female	1.93	0	NC*	Female	7.28	7	96
Total	7.35	5	68	Total	13.62	17	125
Hodgkin's Disease	(Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	2.41	1	NC*	Male	92.51	88	95
Female	1.97	3	NC*				
Total	4.38	4	NC*				
Kidney and Renal F	<u>Pelvis</u>			<u>Stomach</u>			
Male	8.99	14	156	Male	6.39	11	172
Female	6.03	3	NC*	Female	4.30	5	116
Total	15.02	17	113	Total	10.69	16	150
<u>Larynx</u>				<u>Testis</u>			
Male	5.09	6	118	Male	3.72	4	NC*
Female	1.37	2	NC*				
Total	6.46	8	124				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	7.27	9	124	Male	2.09	2	NC*
Female	6.09	3	NC*	Female	5.80	11	190
Total	13.36	12	90	Total	7.89	13	165

Liver and Intrahepation	Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	3.48	2	NC*					
Female	1.59	2	NC*	Female	19.08	21	110	
Total	5.07	4	NC*					
Lung and Bronchus				All Sites / Types				
Male	47.44	49	103	Male	305.02	313	103	
Female	41.47	41	99	Female	314.55	320	102	
Total	88.91	90	101	Total	619.57	633	102	

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

MillburyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	8.43	9	107	Male	5.47	4	NC*
Female	3.47	0	NC*	Female	4.44	4	NC*
Total	11.90	9	76	Total	9.91	8	81
Brain and Other Cer	ntral Nervous S	<u>iystem</u>		Multiple Myeloma			
Male	2.43	0	NC*	Male	1.62	0	NC*
Female	2.08	1	NC*	Female	1.54	0	NC*
Total	4.51	1	NC*	Total	3.16	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.39	0	NC*	Male	6.66	5	75
Female	53.51	47	88	Female	6.46	7	108
Total	53.90	47	87	Total	13.12	12	91
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	5.10	4	NC*
Female	2.96	4	NC*	Female	2.68	3	NC*
				Total	7.79	7	90
Colon / Rectum				<u>Ovary</u>			
Male	20.90	22	105				
Female	21.73	11	51 #-	Female	6.21	8	129
Total	42.62	33	77				
Esophagus Page 1				<u>Pancreas</u>			
Male	2.98	4	NC*	Male	3.52	2	NC*
Female	1.06	1	NC*	Female	4.01	4	NC*
Total	4.04	5	124	Total	7.53	6	80
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	1.21	1	NC*	Male	51.80	42	81
Female	1.00	2	NC*				
Total	2.21	3	NC*				
Kidney and Renal P	<u>'elvis</u>			<u>Stomach</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	4.82	7	145	Male	3.55	2	NC*
Female	3.27	7	214	Female	2.37	3	NC*
Total	8.10	14	173	Total	5.92	5	84
<u>Larynx</u>				<u>Testis</u>			
Male	2.76	2	NC*	Male	1.81	1	NC*
Female	0.75	1	NC*				
Total	3.51	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.89	2	NC*	Male	1.07	2	NC*
Female	3.27	2	NC*	Female	2.98	1	NC*
Total	7.16	4	NC*	Total	4.05	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	1.88	1	NC*				
Female	0.87	0	NC*	Female	10.34	12	116
Total	2.75	1	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	26.36	30	114	Male	168.00	151	90
Female	22.52	27	120	Female	170.06	158	93
Total	48.88	57	117	Total	338.06	309	91

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Millis
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.88	4	NC*	Male	2.92	4	NC*
Female	1.32	1	NC*	Female	2.19	4	NC*
Total	5.20	5	96	Total	5.11	8	157
Brain and Other Cer	<u>ntral Nervous S</u>	<u>System</u>		Multiple Myeloma			
Male	1.39	3	NC*	Male	0.79	1	NC*
Female	1.05	0	NC*	Female	0.64	1	NC*
Total	2.44	3	NC*	Total	1.43	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	0.19	0	NC*	Male	3.49	5	143
Female	25.47	30	118	Female	2.80	5	179
Total	25.66	30	117	Total	6.28	10	159
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	2.80	1	NC*
Female	1.60	1	NC*	Female	1.20	0	NC*
				Total	3.99	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	9.81	7	71				

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Female	8.22	11	134	Female	3.02	6	199
Total	18.03	18	100				
Esophagus				<u>Pancreas</u>			
Male	1.53	2	NC*	Male	1.71	2	NC*
Female	0.40	3	NC*	Female	1.53	1	NC*
Total	1.93	5	259	Total	3.25	3	NC*
Hodgkin's Disease	(Hodgkin Lympl	homa)		<u>Prostate</u>			
Male	0.74	1	NC*	Male	25.85	28	108
Female	0.55	1	NC*				
Total	1.30	2	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	2.54	2	NC*	Male	1.69	2	NC*
Female	1.45	5	344 #+	Female	0.88	1	NC*
Total	4.00	7	175	Total	2.57	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.47	1	NC*	Male	1.16	3	NC*
Female	0.35	0	NC*				
Total	1.82	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.02	2	NC*	Male	0.64	0	NC*
Female	1.46	0	NC*	Female	1.68	3	NC*
Total	3.48	2	NC*	Total	2.32	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	0.99	0	NC*				
Female	0.35	0	NC*	Female	4.90	3	NC*
Total	1.34	0	NC*				
Lung and Bronchus	<u> </u>			All Sites / Types			
Male	12.91	14	108	Male	84.16	92	109
Female	9.81	8	82	Female	75.94	93	122
Total	22.72	22	97	Total	160.10	185	116

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} < 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

MillvilleExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	1.20	0	NC*	Male	0.96	1	NC*
Female	0.48	0	NC*	Female	0.79	2	NC*
Total	1.68	0	NC*	Total	1.75	3	NC*
Brain and Other Cen	tral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	0.48	1	NC*	Male	0.25	0	NC*
Female	0.39	0	NC*	Female	0.22	0	NC*

 $^{^{\}star}$ = SIR and statistical significance not calculated when **Obs** < 5

Total	0.86	1	NC*	Total	0.47	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	mphoma		
Male	0.06	0	NC*	Male	1.15	0	NC*
Female	8.75	7	80	Female	1.01	1	NC*
Total	8.81	7	79	Total	2.16	1	NC*
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	0.90	0	NC*
Female	0.58	1	NC*	Female	0.42	0	NC*
				Total	1.32	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	3.06	4	NC*				
Female	2.99	3	NC*	Female	1.05	0	NC*
Total	6.06	7	116				
Esophagus				<u>Pancreas</u>			
Male	0.48	0	NC*	Male	0.53	0	NC*
Female	0.14	0	NC*	Female	0.55	0	NC*
Total	0.63	0	NC*	Total	1.09	0	NC*
Hodgkin's Disease (Hodgkin Lymph	<u>ioma)</u>		Prostate			
Male	0.27	0	NC*	Male	8.10	4	NC*
Female	0.22	0	NC*				
Total	0.49	0	NC*				
Kidney and Renal Po	<u>elvis</u>			<u>Stomach</u>			
Male	0.82	0	NC*	Male	0.53	0	NC*
Female	0.51	0	NC*	Female	0.33	0	NC*
Total	1.33	0	NC*	Total	0.85	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.47	0	NC*	Male	0.45	0	NC*
Female	0.12	0	NC*				
Total	0.58	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.67	2	NC*	Male	0.23	0	NC*
Female	0.54	1	NC*	Female	0.63	1	NC*
Total	1.21	3	NC*	Total	0.85	1	NC*
Liver and Intrahepat	ic Bile Ducts			Uteri, Corpus and U	<u>terus, NOS</u>		
Male	0.32	0	NC*				
Female	0.13	0	NC*	Female	1.65	1	NC*
Total	0.44	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	4.07	6	147	Male	26.83	19	71
Female	3.37	0	NC*	Female	26.72	20	75
Total	7.44	6	81	Total	53.55	39	73 #-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels

^{* =} SIR and statistical significance not calculated when **Obs** < 5

MiltonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	19.47	14	72	Male	12.31	19	154
Female	8.24	16	194 #+	Female	10.00	11	110
Total	27.70	30	108	Total	22.31	30	134
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	5.37	4	NC*	Male	3.74	3	NC*
Female	4.71	7	149	Female	3.63	1	NC*
Total	10.08	11	109	Total	7.37	4	NC*
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	0.90	3	NC*	Male	14.97	13	87
Female	123.12	142	115	Female	15.05	16	106
Total	124.02	145	117	Total	30.02	29	97
Cervix Uteri				Oral Cavity and Pha			
				Male	11.54	9	78
Female	6.46	6	93	Female	6.24	5	80
				Total	17.78	14	79
Colon / Rectum				<u>Ovary</u>			
Male	48.06	49	102				
Female	51.66	50	97	Female	14.18	18	127
Total	99.73	99	99				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	6.79	6	88	Male	8.06	7	87
Female	2.53	0	NC*	Female	9.52	2	NC*
Total	9.31	6	64	Total	17.58	9	51 #-
Hodgkin's Disease				<u>Prostate</u>			
Male	2.55	6	236	Male	118.22	125	106
Female	2.12	0	NC*				
Total	4.66	6	129				
Kidney and Renal P				<u>Stomach</u>			
Male	11.01	9	82	Male	8.14	4	NC*
Female	7.63	8	105	Female	5.60	7	125
Total	18.63	17	91	Total	13.74	11	80
<u>Larynx</u>		_		<u>Testis</u>			
Male -	6.29	7	111	Male	3.66	2	NC*
Female	1.74	2	NC*				
Total	8.03	9	112	- 1 · 1			
<u>Leukemia</u>	0.00	^	400	<u>Thyroid</u>	0.00	•	NO*
Male	8.82	9	102	Male	2.30	2	NC*
Female	7.55	5	66	Female	6.38	7	110
Total	16.36	14	86	Total	8.68	9	104
Liver and Intrahepa		F	447	Uteri, Corpus and U	iterus, NOS		
Male	4.28	5	117 NC*	Famala	24.00	04	00
Female	2.05	1	NC*	Female	24.00	21	88
Total	6.33	6	95	All Cites / Tomas			
Lung and Bronchus Male		44	73 #-	<u>All Sites / Types</u> Male	383 60	369	96
	60.48				382.69		
Female	52.98 112.47	52 06	98 95	Female	394.80	410 770	104
Total	113.47	96	85	Total	777.49	779	100

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Monroe
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	Obs	SIR
Bladder, Urinary		<u> </u>		Melanoma of Skin			
Male	0.15	0	NC*	Male	0.07	0	NC*
Female	0.04	0	NC*	Female	0.04	0	NC*
Total	0.19	0	NC*	Total	0.11	0	NC*
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.03	0	NC*	Male	0.03	0	NC*
Female	0.02	0	NC*	Female	0.02	0	NC*
Total	0.05	0	NC*	Total	0.04	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.01	0	NC*	Male	0.09	0	NC*
Female	0.48	1	NC*	Female	0.06	0	NC*
Total	0.49	1	NC*	Total	0.16	0	NC*
Cervix Uteri				Oral Cavity and Phary			
				Male	0.06	0	NC*
Female	0.02	0	NC*	Female	0.03	0	NC*
				Total	0.09	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	0.35	0	NC*				
Female	0.24	0	NC*	Female	0.05	0	NC*
Total	0.59	0	NC*				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	0.04	0	NC*	Male	0.06	0	NC*
Female	0.01	0	NC*	Female	0.04	0	NC*
Total	0.05	0	NC*	Total	0.10	0	NC*
Hodgkin's Disease (<u>homa)</u>		<u>Prostate</u>			
Male	0.01	0	NC*	Male	0.71	1	NC*
Female	0.01	0	NC*				
Total	0.02	0	NC*				
Kidney and Renal P				<u>Stomach</u>			
Male	0.07	1	NC*	Male	0.06	0	NC*
Female	0.03	0	NC*	Female	0.02	0	NC*
Total	0.10	1	NC*	Total	0.09	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.03	0	NC*	Male	0.01	0	NC*
Female	0.01	0	NC*				
Total	0.04	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	0.06	0	NC*	Male	0.01	0	NC*
Female	0.03	0	NC*	Female	0.02	0	NC*
Total	0.09	0	NC*	Total	0.03	0	NC*
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and Ut	erus, NOS		
Male	0.03	0	NC*	-			
Female	0.01	0	NC*	Female	0.10	0	NC*
Total	0.03	0	NC*				
Lung and Bronchus	i			All Sites / Types			
Male	0.39	1	NC*	Male	2.46	3	NC*
Female	0.23	0	NC*	Female	1.63	1	NC*
Total	0.63	1	NC*	Total	4.09	4	NC*

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

MonsonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	5.22	4	NC*	Male	3.90	9	231 #+
Female	1.80	0	NC*	Female	2.83	4	NC*
Total	7.02	4	NC*	Total	6.74	13	193 #+
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	1.79	1	NC*	Male	1.08	0	NC*
Female	1.33	1	NC*	Female	0.87	2	NC*
Total	3.13	2	NC*	Total	1.95	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	nphoma		
Male	0.26	0	NC*	Male	4.60	2	NC*
Female	33.72	25	74	Female	3.71	3	NC*
Total	33.98	25	74	Total	8.31	5	60
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	3.79	2	NC*
Female	2.02	5	247	Female	1.60	3	NC*
				Total	5.39	5	93
Colon / Rectum				<u>Ovary</u>			
Male	13.16	7	53				
Female	11.27	7	62	Female	3.95	2	NC*
Total	24.42	14	57 #-				
Esophagus				<u>Pancreas</u>			
Male	2.07	2	NC*	Male	2.30	2	NC*
Female	0.54	0	NC*	Female	2.09	2	NC*
Total	2.62	2	NC*	Total	4.39	4	NC*
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	0.91	3	NC*	Male	34.71	22	63 #-

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	0.67	2	NC*				
Total	1.58	5	316 #+				
Kidney and Renal Pe	<u>elvis</u>			Stomach			
Male	3.45	2	NC*	Male	2.27	2	NC*
Female	1.93	2	NC*	Female	1.21	5	414 #+
Total	5.38	4	NC*	Total	3.48	7	201
<u>Larynx</u>				<u>Testis</u>			
Male	2.00	2	NC*	Male	1.39	2	NC*
Female	0.46	1	NC*				
Total	2.46	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.63	5	190	Male	0.83	2	NC*
Female	1.91	1	NC*	Female	2.09	2	NC*
Total	4.54	6	132	Total	2.92	4	NC*
Liver and Intrahepat	ic Bile Ducts			Uteri, Corpus and L	<u>Iterus, NOS</u>		
Male	1.33	1	NC*				
Female	0.47	1	NC*	Female	6.53	7	107
Total	1.80	2	NC*				
Lung and Bronchus				All Sites / Types			
Male	17.39	13	75	Male	112.48	87	77 #-
Female	13.10	25	191 ~+	Female	100.97	107	106
Total	30.49	38	125	Total	213.44	194	91

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

MontagueExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinary				Melanoma of Skin					
Male	5.96	8	134	Male	3.67	4	NC*		
Female	2.41	3	NC*	Female	2.82	6	213		
Total	8.37	11	131	Total	6.49	10	154		
Brain and Other Cen	<u>itral Nervous S</u>	<u>ystem</u>		Multiple Myeloma					
Male	1.58	1	NC*	Male	1.13	0	NC*		
Female	1.38	0	NC*	Female	1.06	0	NC*		
Total	2.96	1	NC*	Total	2.19	0	NC*		
<u>Breast</u>				Non-Hodgkin('s) Lym	phoma				
Male	0.27	0	NC*	Male	4.49	5	111		
Female	34.91	34	97	Female	4.40	9	204		
Total	35.18	34	97	Total	8.89	14	157		
Cervix Uteri				Oral Cavity and Pharynx					
				Male	3.40	3	NC*		
Female	1.80	2	NC*	Female	1.79	0	NC*		

^{* =} SIR and statistical significance not calculated when **Obs** < 5

				Total	5.19	3	NC*
Colon / Rectum				<u>Ovary</u>			
Male	14.65	14	96				
Female	15.12	19	126	Female	4.04	4	NC*
Total	29.78	33	111				
Esophagus				<u>Pancreas</u>			
Male	2.02	1	NC*	Male	2.43	2	NC*
Female	0.74	0	NC*	Female	2.80	3	NC*
Total	2.76	1	NC*	Total	5.23	5	96
Hodgkin's Disease	(Hodgkin Lympl	noma)		<u>Prostate</u>			
Male	0.74	0	NC*	Male	35.35	30	85
Female	0.61	1	NC*				
Total	1.35	1	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	3.29	2	NC*	Male	2.47	0	NC*
Female	2.22	1	NC*	Female	1.62	0	NC*
Total	5.51	3	NC*	Total	4.09	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.86	7	376 ~+	Male	1.07	1	NC*
Female	0.51	0	NC*				
Total	2.37	7	296 #+				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.66	3	NC*	Male	0.67	1	NC*
Female	2.19	2	NC*	Female	1.77	2	NC*
Total	4.85	5	103	Total	2.44	3	NC*
Liver and Intrahepa	<u>tic Bile Ducts</u>			Uteri, Corpus and U	<u>lterus, NOS</u>		
Male	1.27	1	NC*				
Female	0.60	0	NC*	Female	6.85	16	234 ~+
Total	1.88	1	NC*				
Lung and Bronchus	="			All Sites / Types			
Male	18.27	22	120	Male	115.09	114	99
Female	15.65	14	89	Female	113.80	123	108
Total	33.92	36	106	Total	228.89	237	104

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

MontereyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.79	0	NC*	Male	0.49	0	NC*
Female	0.23	0	NC*	Female	0.32	0	NC*
Total	1.02	0	NC*	Total	0.81	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Brain and Other Cer	ntral Nervous Sy	<u>/stem</u>		Multiple Myeloma				
Male	0.21	1	NC*	Male	0.15	0	NC*	
Female	0.15	0	NC*	Female	0.11	0	NC*	
Total	0.36	1	NC*	Total	0.26	0	NC*	
<u>Breast</u>				Non-Hodgkin('s) Lyr	mphoma			
Male	0.04	0	NC*	Male	0.60	1	NC*	
Female	4.10	3	NC*	Female	0.45	0	NC*	
Total	4.13	3	NC*	Total	1.05	1	NC*	
Cervix Uteri				Oral Cavity and Pharynx				
				Male	0.46	0	NC*	
Female	0.21	0	NC*	Female	0.20	1	NC*	
				Total	0.66	1	NC*	
Colon / Rectum				<u>Ovary</u>				
Male	1.95	3	NC*					
Female	1.44	2	NC*	Female	0.47	0	NC*	
Total	3.39	5	147					
Esophagus				<u>Pancreas</u>				
Male	0.28	1	NC*	Male	0.33	0	NC*	
Female	0.07	0	NC*	Female	0.28	0	NC*	
Total	0.35	1	NC*	Total	0.60	0	NC*	
Hodgkin's Disease (Hodgkin Lymph	noma)		Prostate				
Male	0.10	0	NC*	Male	4.79	3	NC*	
Female	0.06	0	NC*					
Total	0.16	0	NC*					
Kidney and Renal Po	elvis			<u>Stomach</u>				
Male	0.44	0	NC*	Male	0.33	0	NC*	
Female	0.24	0	NC*	Female	0.15	0	NC*	
Total	0.68	0	NC*	Total	0.49	0	NC*	
<u>Larynx</u>				<u>Testis</u>				
Male	0.25	0	NC*	Male	0.14	0	NC*	
Female	0.06	0	NC*					
Total	0.31	0	NC*					
<u>Leukemia</u>				<u>Thyroid</u>				
Male	0.34	1	NC*	Male	0.09	0	NC*	
Female	0.23	1	NC*	Female	0.20	0	NC*	
Total	0.57	2	NC*	Total	0.29	0	NC*	
Liver and Intrahepat				Uteri, Corpus and Ut				
Male	0.17	0	NC*					
Female	0.06	0	NC*	Female	0.82	0	NC*	
Total	0.23	0	NC*					
Lung and Bronchus		-	-	All Sites / Types				
Male	2.43	1	NC*	Male	15.39	12	78	
Female	1.70	0	NC*	Female	12.40	7	56	
Total	4.13	1	NC*	Total	27.79	19	68	
. 5(4)		•		1000			50	

Obs = observed case count

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $p \le 0.05$ level

~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

 \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

MontgomeryExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR		
Bladder, Urinary				Melanoma of Skin					
Male	0.54	0	NC*	Male	0.36	0	NC*		
Female	0.19	0	NC*	Female	0.26	0	NC*		
Total	0.72	0	NC*	Total	0.61	0	NC*		
Brain and Other Centra		ystem		Multiple Myeloma					
Male	0.15	1	NC*	Male	0.11	0	NC*		
Female	0.12	0	NC*	Female	0.09	0	NC*		
Total	0.27	1	NC*	Total	0.19	0	NC*		
Breast				Non-Hodgkin('s) Lym					
Male	0.03	0	NC*	Male	0.42	0	NC*		
Female	3.16	3	NC*	Female	0.36	0	NC*		
Total	3.19	3	NC*	Total	0.78	0	NC*		
Cervix Uteri	••	· ·		Oral Cavity and Phar		·			
<u> </u>				Male	0.34	0	NC*		
Female	0.17	0	NC*	Female	0.15	0	NC*		
Tomaio	0.17	O	110	Total	0.49	0	NC*		
Colon / Rectum				<u>Ovary</u>	0.43	U	NO		
Male	1.32	2	NC*	<u>Ovary</u>					
Female	1.17	0	NC*	Female	0.36	1	NC*		
Total	2.49	2	NC*	remale	0.50	'	NC		
	2.49	2	INC	Donorooo					
<u>Esophagus</u>	0.40	0	NO*	<u>Pancreas</u>	0.00	0	NOt		
Male	0.19	0	NC*	Male	0.22	0	NC*		
Female	0.06	0	NC*	Female	0.22	0	NC*		
Total	0.25	0	NC*	Total	0.44	0	NC*		
Hodgkin's Disease (Ho				<u>Prostate</u>		_			
Male	0.07	0	NC*	Male	3.29	3	NC*		
Female	0.05	0	NC*						
Total	0.13	0	NC*						
Kidney and Renal Pelv				<u>Stomach</u>					
Male	0.32	0	NC*	Male	0.22	0	NC*		
Female	0.19	0	NC*	Female	0.13	0	NC*		
Total	0.51	0	NC*	Total	0.35	0	NC*		
<u>Larynx</u>				<u>Testis</u>					
Male	0.18	0	NC*	Male	0.10	1	NC*		
Female	0.04	0	NC*						
Total	0.23	0	NC*						
<u>Leukemia</u>				Thyroid					
Male	0.25	0	NC*	Male	0.07	0	NC*		
Female	0.18	1	NC*	Female	0.17	0	NC*		
Total	0.43	1	NC*	Total	0.24	0	NC*		
Liver and Intrahepatic		•		Uteri, Corpus and Ute		·			
Male	0.12	0	NC*						
Female	0.05	0	NC*	Female	0.62	0	NC*		
Total	0.17	0	NC*	· Siller	<u>-</u>	J	0		
Lung and Bronchus	V.11	J	.10	All Sites / Types					
Male	1.70	1	NC*	Male	10.73	8	75		
iviaic	1.70	I	NO	iviaic	10.70	U	13		

Female	1.28	1	NC*	Female	9.70	6	62
Total	2.98	2	NC*	Total	20.44	14	68

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

Mount WashingtonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

Signatury		=/4 0000000		,				
Male 0.19 0 NC* Male 0.11 0 NC* Female 0.05 0 NC* Female 0.06 0 NC* Total 0.24 0 NC* Total 0.17 0 NC* Brain and Other Central Nervous System Multiple Myeloma Male 0.04 0 NC* Female 0.02 0 NC* Female 0.03 0 NC* Female 0.02 0 NC* Total 0.07 0 NC* Total 0.06 0 NC* Female 0.03 0 NC* Female 0.02 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Female 0.80 0 NC* Female 0.02 0 NC* Female 0.04 0 NC* Female 0.04 0 NC*		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Female Total 0.05 (0.24) 0 NC* Female Total 0.01 0 NC* Brain and Other Central Nervous System Multiple Myeloma Male 0.04 0 NC* Male 0.04 0 NC* Female 0.03 0 NC* Female 0.02 0 NC* Total 0.07 0 NC* Total 0.06 0 NC* Breast Non-Hodgkin/'s) Lymphoma Male 0.01 0 NC* Male 0.13 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Total 0.81 0 NC* Female 0.09 1 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.35 1 NC* Female 0.09 0 NC* Female 0.35	Bladder, Urinary				Melanoma of Skin			
Total 0.24 0 NC* Total 0.17 0 NC* Brain and Other Central Nervous System Male 0.04 0 NC* Male 0.04 0 NC* Female 0.03 0 NC* Female 0.02 0 NC* Total 0.07 0 NC* Total 0.06 0 NC* Brast Non-Hodgkin('s) Lymphoma Male 0.01 0 NC* Male 0.13 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Total 0.81 0 NC* Female 0.03 1 NC* Female 0.04 0 NC* Female 0.01 0 NC* Female 0.04 0 NC* Female 0.09 0 NC* Female 0.45 0 NC* Female 0.09	Male	0.19	0		Male	0.11	0	NC*
Brain and Other Central Nervous System Multiple Myeloma Male 0.04 0 NC* Male 0.04 0 NC* Female 0.03 0 NC* Female 0.02 0 NC* Total 0.07 0 NC* Total 0.06 0 NC* Breast Non-Hodgkin('s) Lymbrum Male 0.01 0 NC* Male 0.13 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Female 0.81 0 NC* Female by make 0.01 NC* Female 0.01 0 NC* Female 0.01 NC* Female 0.04 0 NC* Female 0.04 NC* Female 0.04 0 NC* Female 0.09 NC* Female 0.02 0 NC* Female 0.09	Female	0.05	0	NC*	Female	0.06	0	NC*
Male 0.04 0 NC* Male 0.04 0 NC* Female 0.03 0 NC* Female 0.02 0 NC* Total 0.07 0 NC* Total 0.06 0 NC* Breast Non-Hodgkin's) Lymphoma Male 0.01 0 NC* Male 0.03 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Total 0.81 0 NC* Total 0.23 1 NC* Eenale 0.80 0 NC* Female 0.09 1 NC* Eenale 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.05 NC* Female 0.09 0 NC* Female 0.07 N	Total	0.24	0	NC*	Total	0.17	0	NC*
Female Total 0.03 0 NC* NC* Female Total 0.02 0 NC* NC* Breast Non-Hodgkin('s) Lymphoma Male 0.01 0 NC* Male 0.13 0 NC* NC* Male 0.13 0 NC*	Brain and Other Cen	tral Nervous S	<u>System</u>		Multiple Myeloma			
Total 0.07 0 NC* Total 0.06 0 NC* Breast Non-Hodgkin('s) Lymphoma Male 0.01 0 NC* Male 0.13 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Total 0.81 0 NC* Female 0.09 1 NC* Eervix Uteri Doral Cavity and Pharymx W Male 0.11 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.45 0 NC* Female 0.09 NC* NC* Female 0.32 1 NC* Female 0.09 NC* Male 0.07 0 NC* Female 0.06 NC* Female 0.02	Male	0.04	0	NC*	Male	0.04	0	NC*
Breast Non-Hodgkin('s) Lymbums Male 0.01 0 NC* Male 0.13 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Total 0.81 0 NC* Female 0.09 1 NC* Cervix Uteri Bale 0.11 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.45 0 NC* Female 0.04 0 NC* Female 0.45 0 NC* Female 0.09 0 NC* Female 0.32 1 NC* Female 0.09 NC* Total 0.78 1 NC* Female 0.06 NC* Female 0.07 0 NC* Female 0.06 <t< td=""><td>Female</td><td>0.03</td><td>0</td><td>NC*</td><td>Female</td><td>0.02</td><td>0</td><td>NC*</td></t<>	Female	0.03	0	NC*	Female	0.02	0	NC*
Male 0.01 0 NC* Male 0.13 0 NC* Female 0.80 0 NC* Female 0.09 1 NC* Total 0.81 0 NC* Total 0.23 1 NC* Cervix Uteri Male 0.11 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Total 0.15 0 NC* Male 0.45 0 NC* Female 0.09 0 NC* Female 0.32 1 NC* Female 0.09 0 NC* Female 0.07 0 NC* Female 0.08 0 NC* Female 0.02 0 NC* Total 0.14 0 NC* <td>Total</td> <td>0.07</td> <td>0</td> <td>NC*</td> <td>Total</td> <td>0.06</td> <td>0</td> <td>NC*</td>	Total	0.07	0	NC*	Total	0.06	0	NC*
Female Total 0.80 0 NC* NC* Female Total 0.09 1 NC* NC* Cervix Uteri Carl Cavity and Pharytt Female 0.04 0 NC* NC* Female Total 0.11 0 NC* Female 0.04 0 NC* Female Total 0.01 0 NC* Colon / Rectum Covary Male 0.45 0 NC* Female 0.09 0 NC* Female 0.32 1 NC* Female 0.09 0 NC* Total 0.78 1 NC* Female 0.09 0 NC* Female 0.02 1 NC* Female 0.09 0 NC* Female 0.07 0 NC* Female 0.06 NC* Total 0.08 0 NC* Total 1.09 NC* Male 0.01 0 NC* Male 1.09	<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Total 0.81 0 NC* Total 0.23 1 NC* Cervix Uteri Oral Cavity and Pharym Color Pecture Male 0.11 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Colon / Recture Overy Male 0.45 0 NC* Female 0.09 0 NC* Female 0.32 1 NC* Female 0.09 0 NC* Female on 0.78 1 NC* Female 0.09 0 NC* Female on 0.78 0 NC* Female 0.09 0 NC* Female on 0.07 0 NC* Female 0.06 0 NC* Female on 0.02 0 NC* Female 0.06 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) NC* Male 1.09 0 NC* Female on 0.01 0.01 NC* Male	Male	0.01	0	NC*	Male	0.13	0	NC*
Cervix Uteri Oral Cavity and Pharyms Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Female 0.04 0 NC* Colon / Rectum Ovary Male 0.45 0 NC* Female 0.09 0 NC* Female 0.32 1 NC* Female 0.09 0 NC* Total 0.78 1 NC* Female 0.09 0 NC* Esophagus Pancreas Male 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 NC* Hodgkin's Disease/Hodgkin Lymphoma Prostate Prostate 1 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Female 0.01 0	Female	0.80	0	NC*	Female	0.09	1	NC*
Female 0.04 0 NC* Female 0.04 0 NC*	Total	0.81	0	NC*	Total	0.23	1	NC*
Female 0.04 0 NC* Female 0.04 0 NC* Colon / Rectum Ovary Male 0.45 0 NC* Female 0.09 0 NC* Female 0.32 1 NC* Female 0.09 0 NC* Total 0.78 1 NC* Female 0.09 0 NC* Bale 0.07 0 NC* Female 0.09 0 NC* Female 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) 0 NC* Total 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 0.08 0 NC* Kidney and Renal Pet/s	Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
Total 0.15 0 NC* Colon / Rectum Ovary Colon / Rectum Ovary Colon / Rectum Colo					Male	0.11	0	NC*
Colon / Rectum Ovary Male 0.45 0 NC* Female 0.32 1 NC* Female 0.09 0 NC* Total 0.78 1 NC* Female 0.09 0 NC* Male 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 0 NC* Total 0.08 0 NC* Female 0.06 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) NC* Prostate 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Kidney and Renal Pelvis Stomach Female 0.05 0 NC* Female 0.03 1 NC* Female 0.05 0<	Female	0.04	0	NC*	Female	0.04	0	NC*
Male 0.45 0 NC* Female 0.09 0 NC* Female 0.32 1 NC* Female 0.09 0 NC* Total 0.78 1 NC* Female 0.09 0 NC* Male 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) NC* Prostate 0.04 0 NC* Male 0.02 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Kidney and Renal Pelvis Stomach Female 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Female 0.05					Total	0.15	0	NC*
Female 0.32 1 NC* Female 0.09 0 NC* Esophagus Pancreas Male 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate 0 NC*	Colon / Rectum				<u>Ovary</u>			
Total 0.78 1 NC* Esophagus Pancreas Male 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 0 NC* Total 0.08 0 NC* Total 0.10 0 NC* Male 0.02 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Kidney and Renal Pelvis Stomach Female 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Female 0.05 0 NC* Total 0.11 1 NC* Total	Male	0.45	0	NC*				
Esophagus Pancreas Male 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 0 NC* Total 0.08 0 NC* Total 0.14 0 NC* Male 0.08 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Kidney and Renal Pelvis Stomach Stomach Stomach Use Total 0.08 0 NC* Female 0.05 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx M	Female	0.32	1	NC*	Female	0.09	0	NC*
Male 0.07 0 NC* Male 0.08 0 NC* Female 0.02 0 NC* Female 0.06 0 NC* Total 0.08 0 NC* Total 0.14 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.02 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Total 0.03 0 NC* NC	Total	0.78	1	NC*				
Female 0.02 0 NC* Female 0.06 0 NC* Total 0.08 0 NC* Total 0.14 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.02 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Kidney and Renal Pelvis Stomach Male 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx Male 0.06 0 NC* Male 0.02 0 NC*	Esophagus				<u>Pancreas</u>			
Total 0.08 0 NC* Total 0.14 0 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.02 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* Male 1.09 0 NC* Kidney and Renal Pelvis Stomach Male 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx Male 0.06 0 NC* Male 0.02 0 NC*	Male	0.07	0	NC*	Male	80.0	0	NC*
Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.02 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* ————————————————————————————————————	Female	0.02	0	NC*	Female	0.06	0	NC*
Male 0.02 0 NC* Male 1.09 0 NC* Female 0.01 0 NC* <td>Total</td> <td>80.0</td> <td>0</td> <td>NC*</td> <td>Total</td> <td>0.14</td> <td>0</td> <td>NC*</td>	Total	80.0	0	NC*	Total	0.14	0	NC*
Female 0.01 0 NC* Total 0.03 0 NC* Stomach Male 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx Testis Male 0.06 0 NC* Male 0.02 0 NC*	Hodgkin's Disease (I	Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Total 0.03 0 NC* Kidney and Renal Pelvis Stomach Male 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx Testis Male 0.06 0 NC* Male 0.02 0 NC*	Male	0.02	0	NC*	Male	1.09	0	NC*
Stomach Male 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx Testis Male 0.06 0 NC* Male 0.02 0 NC*	Female	0.01	0	NC*				
Male 0.10 0 NC* Male 0.08 0 NC* Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx Testis Male 0.06 0 NC* Male 0.02 0 NC*	Total	0.03	0	NC*				
Female 0.05 0 NC* Female 0.03 1 NC* Total 0.15 0 NC* Total 0.11 1 NC* Larynx Testis Male 0.06 0 NC* Male 0.02 0 NC*	Kidney and Renal Pe	<u>elvis</u>			Stomach			
Larynx Total 0.15 0 NC* Total 0.11 1 NC* Larynx Male 0.06 0 NC* Male 0.02 0 NC*	Male	0.10	0	NC*	Male	80.0	0	NC*
Larynx Testis Male 0.06 0 NC* Male 0.02 0 NC*	Female	0.05	0	NC*	Female	0.03	1	NC*
Male 0.06 0 NC* Male 0.02 0 NC*	Total	0.15	0	NC*	Total	0.11	1	NC*
	<u>Larynx</u>				<u>Testis</u>			
Female 0.01 0 NC*	Male	0.06	0	NC*	Male	0.02	0	NC*
	Female	0.01	0	NC*				

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	0.07	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.08	0	NC*	Male	0.02	0	NC*
Female	0.04	0	NC*	Female	0.03	0	NC*
Total	0.12	0	NC*	Total	0.05	0	NC*
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and Ut	erus, NOS		
Male	0.04	0	NC*				
Female	0.01	0	NC*	Female	0.16	0	NC*
Total	0.05	0	NC*				
Lung and Bronchus	1			All Sites / Types			
Male	0.56	0	NC*	Male	3.53	0	NC*
Female	0.34	0	NC*	Female	2.49	4	NC*
Total	0.91	0	NC*	Total	6.02	4	NC*

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Nahant
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.51	4	NC*	Male	2.13	7	329 #+
Female	1.20	1	NC*	Female	1.46	1	NC*
Total	4.71	5	106	Total	3.59	8	223
Brain and Other C	Central Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	0.88	0	NC*	Male	0.66	0	NC*
Female	0.67	1	NC*	Female	0.53	0	NC*
Total	1.55	1	NC*	Total	1.19	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>ıphoma</u>		
Male	0.16	0	NC*	Male	2.59	4	NC*
Female	17.85	19	106	Female	2.20	1	NC*
Total	18.01	19	105	Total	4.79	5	104
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	1.97	3	NC*
Female	0.95	1	NC*	Female	0.90	3	NC*
				Total	2.87	6	209
Colon / Rectum				<u>Ovary</u>			
Male	8.59	9	105				
Female	7.57	10	132	Female	2.06	2	NC*
Total	16.15	19	118				
Esophagus				<u>Pancreas</u>			
Male	1.17	1	NC*	Male	1.42	4	NC*
Female	0.37	0	NC*	Female	1.39	3	NC*
Total	1.54	1	NC*	Total	2.81	7	249

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Hodgkin's Disease	(Hodgkin Lymph	<u>noma)</u>		<u>Prostate</u>			
Male	0.41	0	NC*	Male	20.29	20	99
Female	0.31	0	NC*				
Total	0.72	0	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	1.90	1	NC*	Male	1.46	0	NC*
Female	1.10	1	NC*	Female	0.82	2	NC*
Total	3.00	2	NC*	Total	2.28	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.07	0	NC*	Male	0.58	1	NC*
Female	0.25	1	NC*				
Total	1.32	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.51	0	NC*	Male	0.38	0	NC*
Female	1.07	2	NC*	Female	0.94	1	NC*
Total	2.58	2	NC*	Total	1.32	1	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	0.73	0	NC*				
Female	0.30	0	NC*	Female	3.46	2	NC*
Total	1.03	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	10.55	8	76	Male	66.49	66	99
Female	7.69	7	91	Female	57.38	66	115
Total	18.24	15	82	Total	123.87	132	107

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Nantucket
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.90	2	NC*	Male	3.33	7	210
Female	1.84	5	272	Female	2.54	9	355 ~+
Total	6.74	7	104	Total	5.86	16	273 ^+
Brain and Other Cer	<u>itral Nervous S</u>	<u>ystem</u>		Multiple Myeloma			
Male	1.47	4	NC*	Male	0.96	0	NC*
Female	1.18	2	NC*	Female	0.82	1	NC*
Total	2.65	6	227	Total	1.79	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.23	0	NC*	Male	4.01	3	NC*
Female	29.72	32	108	Female	3.53	8	226
Total	29.95	32	107	Total	7.54	11	146
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

				Male	3.14	6	191
Female	1.76	1	NC*	Female	1.47	2	NC*
				Total	4.60	8	174
Colon / Rectum				<u>Ovary</u>			
Male	12.14	8	66				
Female	11.53	8	69	Female	3.48	2	NC*
Total	23.67	16	68				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	1.78	1	NC*	Male	2.07	3	NC*
Female	0.56	1	NC*	Female	2.12	4	NC*
Total	2.34	2	NC*	Total	4.20	7	167
Hodgkin's Disease	(Hodgkin Lympl	<u>homa)</u>		<u>Prostate</u>			
Male	0.74	3	NC*	Male	29.92	31	104
Female	0.61	0	NC*				
Total	1.35	3	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	2.92	4	NC*	Male	2.10	2	NC*
Female	1.78	2	NC*	Female	1.26	0	NC*
Total	4.70	6	128	Total	3.36	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.66	2	NC*	Male	1.12	3	NC*
Female	0.41	0	NC*				
Total	2.07	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.31	6	260	Male	0.67	1	NC*
Female	1.78	5	281	Female	1.81	2	NC*
Total	4.09	11	269 ~+	Total	2.48	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.13	0	NC*				
Female	0.46	0	NC*	Female	5.68	8	141
Total	1.59	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	15.29	20	131	Male	98.58	110	112
Female	12.16	16	132	Female	93.25	115	123 #+
Total	27.45	36	131	Total	191.83	225	117 #+

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

Natick Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	19.87	20	101	Male	13.51	16	118

^{* =} SIR and statistical significance not calculated when **Obs** < 5

 $[\]land$ indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

Female	7.81	3	NC*	Female	10.74	20	186 #+
Total	27.68	23	83	Total	24.25	36	148 #+
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	6.10	6	98	Male	3.90	3	NC*
Female	5.07	4	NC*	Female	3.55	3	NC*
Total	11.17	10	90	Total	7.46	6	80
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	0.94	0	NC*	Male	16.29	15	92
Female	127.70	166	130 ~+	Female	15.14	19	126
Total	128.65	166	129 ~+	Total	31.43	34	108
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	12.55	20	159
Female	7.41	3	NC*	Female	6.29	11	175
				Total	18.84	31	165 #+
Colon / Rectum				<u>Ovary</u>			
Male	49.54	60	121				
Female	48.99	45	92	Female	14.94	25	167 #+
Total	98.53	105	107				
Esophagus Page 1				<u>Pancreas</u>			
Male	7.19	5	70	Male	8.37	10	120
Female	2.38	4	NC*	Female	9.06	6	66
Total	9.57	9	94	Total	17.43	16	92
Hodgkin's Disease	(Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	3.15	1	NC*	Male	124.74	135	108
Female	2.53	6	237				
Total	5.68	7	123				
Kidney and Renal F	<u>Pelvis</u>			<u>Stomach</u>			
Male	11.86	8	67	Male	8.36	4	NC*
Female	7.68	8	104	Female	5.29	6	113
Total	19.55	16	82	Total	13.65	10	73
<u>Larynx</u>				<u>Testis</u>			
Male	6.78	3	NC*	Male	4.91	5	102
Female	1.78	1	NC*				
Total	8.55	4	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	9.46	10	106	Male	2.75	3	NC*
Female	7.59	10	132	Female	7.58	10	132
Total	17.06	20	117	Total	10.33	13	126
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	4.60	5	109				
Female	1.98	4	NC*	Female	24.64	23	93
Total	6.59	9	137				
Lung and Bronchu	 '			All Sites / Types			
Male	63.59	60	94	Male	405.74	421	104
Female	52.94	56	106	Female	399.75	469	117 ^+
Total	116.53	116	100	Total	805.49	890	110 ~+

Obs = observed case count

 $[\]mbox{\ensuremath{^{\star}}}$ = SIR and statistical significance not calculated when $\mbox{\ensuremath{\mathbf{Obs}}}$ < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Needham
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	21.75	18	83	Male	13.64	16	117
Female	8.72	5	57	Female	10.63	14	132
Total	30.47	23	75	Total	24.27	30	124
Brain and Other Ce	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	5.91	10	169	Male	4.19	6	143
Female	4.97	14	282 ~+	Female	3.85	2	NC*
Total	10.88	24	221 ^+	Total	8.05	8	99
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	1.01	1	NC*	Male	16.53	10	61
Female	132.05	141	107	Female	15.87	17	107
Total	133.06	142	107	Total	32.40	27	83
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	12.98	11	85
Female	6.82	5	73	Female	6.67	4	NC*
				Total	19.65	15	76
Colon / Rectum				Ovary			
Male	53.79	43	80				
Female	54.55	47	86	Female	15.14	22	145
Total	108.34	90	83				
Esophagus				Pancreas			
Male	7.67	7	91	Male	9.05	2	NC*
Female	2.67	4	NC*	Female	10.05	10	99
Total	10.34	11	106	Total	19.10	12	63
Hodgkin's Disease	(Hodgkin Lymp	homa)		Prostate			
Male	2.66	2	NC*	Male	134.29	169	126 ~+
Female	2.18	3	NC*				
Total	4.84	5	103				
Kidney and Renal F	Pelvis			Stomach			
Male	12.35	16	130	Male	9.09	6	66
Female	8.11	3	NC*	Female	5.94	3	NC*
Total	20.46	19	93	Total	15.02	9	60
Larynx				<u>Testis</u>			
Male	7.13	1	NC*	Male	3.65	5	137
Female	1.86	1	NC*				
Total	8.99	2	NC*				
Leukemia				<u>Thyroid</u>			
Male	9.73	15	154	Male	2.49	6	241
Female	8.04	13	162	Female	6.69	7	105
Total	17.78	28	158 #+	Total	9.19	13	142
Liver and Intrahepa				Uteri, Corpus and U			
Male	4.81	3	NC*	attention of the second of the			
Female	2.17	4	NC*	Female	25.80	22	85
i cilialo	۲.11	7	110	i citiale	20.00		55

Total	6.99	7	100				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	68.22	41	60 ^-	Male	429.38	413	96
Female	56.03	45	80	Female	420.02	422	100
Total	124.25	86	69 ^-	Total	849.40	835	98

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

New Ashford
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.19	0	NC*	Male	0.12	0	NC*
Female	0.05	0	NC*	Female	0.06	0	NC*
Total	0.24	0	NC*	Total	0.18	0	NC*
Brain and Other Cer		<u>ystem</u>		Multiple Myeloma			
Male	0.05	0	NC*	Male	0.04	1	NC*
Female	0.03	0	NC*	Female	0.02	0	NC*
Total	0.08	0	NC*	Total	0.06	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>nphoma</u>		
Male	0.01	0	NC*	Male	0.14	0	NC*
Female	0.75	0	NC*	Female	0.09	0	NC*
Total	0.76	0	NC*	Total	0.24	0	NC*
Cervix Uteri				Oral Cavity and Phar	-		
				Male	0.11	0	NC*
Female	0.04	0	NC*	Female	0.04	0	NC*
				Total	0.15	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	0.48	0	NC*				
Female	0.31	0	NC*	Female	0.09	0	NC*
Total	0.79	0	NC*				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	0.07	0	NC*	Male	0.08	0	NC*
Female	0.01	0	NC*	Female	0.06	0	NC*
Total	0.08	0	NC*	Total	0.14	0	NC*
Hodgkin's Disease				<u>Prostate</u>			
Male	0.02	0	NC*	Male	1.20	0	NC*
Female	0.01	0	NC*				
Total	0.04	0	NC*				
Kidney and Renal P				<u>Stomach</u>			
Male	0.11	0	NC*	Male	0.08	0	NC*
Female	0.05	0	NC*	Female	0.03	0	NC*
Total	0.15	0	NC*	Total	0.11	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

<u>Larynx</u>				<u>Testis</u>			
Male	0.06	0	NC*	Male	0.03	0	NC*
Female	0.01	0	NC*				
Total	0.07	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	80.0	0	NC*	Male	0.02	0	NC*
Female	0.04	0	NC*	Female	0.04	0	NC*
Total	0.13	0	NC*	Total	0.06	0	NC*
Liver and Intrahepat	ic Bile Ducts			Uteri, Corpus and Ut	erus, NOS		
Male	0.04	0	NC*				
Female	0.01	0	NC*	Female	0.15	0	NC*
Total	0.05	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	0.61	0	NC*	Male	3.79	1	NC*
Female	0.33	0	NC*	Female	2.41	0	NC*

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the p ≤ 0.001 level, as well as at the p ≤ 0.05 and p ≤ 0.01 levels

New Bedford
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	69.29	53	76	Male	42.21	25	59 ~-
Female	30.92	28	91	Female	35.50	10	28 ^-
Total	100.20	81	81	Total	77.71	35	45 ^-
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	18.44	19	103	Male	13.00	18	138
Female	17.03	12	70	Female	13.25	11	83
Total	35.47	31	87	Total	26.25	29	110
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>iphoma</u>		
Male	3.11	3	NC*	Male	52.05	41	79
Female	429.63	375	87 ~-	Female	55.28	50	90
Total	432.74	378	87 ~-	Total	107.33	91	85
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	38.42	45	117
Female	22.61	32	142	Female	22.28	24	108
				Total	60.70	69	114
Colon / Rectum				<u>Ovary</u>			
Male	170.06	187	110				
Female	194.72	204	105	Female	49.73	52	105
Total	364.78	391	107				
Esophagus				<u>Pancreas</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	23.03	29	126	Male	28.03	31	111
Female	9.51	9	95	Female	35.60	40	112
Total	32.54	38	117	Total	63.63	71	112
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	8.96	14	156	Male	405.39	348	86 ~-
Female	7.85	9	115				
Total	16.81	23	137				
Kidney and Renal I	<u>Pelvis</u>			Stomach			
Male	37.52	46	123	Male	28.58	45	157 ~+
Female	27.36	21	77	Female	21.21	23	108
Total	64.88	67	103	Total	49.80	68	137 #+
<u>Larynx</u>				<u>Testis</u>			
Male	21.09	35	166 ~+	Male	13.17	12	91
Female	6.03	10	166				
Total	27.12	45	166 ~+				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	31.11	27	87	Male	7.73	8	103
Female	27.80	33	119	Female	22.50	17	76
Total	58.92	60	102	Total	30.24	25	83
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	14.56	12	82				
Female	7.62	12	157	Female	82.94	87	105
Total	22.18	24	108				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	210.37	243	116 #+	Male	1327.42	1313	99
Female	190.38	124	65 ^-	Female	1419.42	1293	91 ^-
Total	400.76	367	92	Total	2746.83	2606	95 ~-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

New Braintree
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.54	1	NC*	Male	0.41	1	NC*
Female	0.17	0	NC*	Female	0.28	0	NC*
Total	0.71	1	NC*	Total	0.69	1	NC*
Brain and Other Cen	tral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	0.19	0	NC*	Male	0.11	0	NC*
Female	0.13	1	NC*	Female	0.08	0	NC*
Total	0.32	1	NC*	Total	0.19	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lymr	<u>ohoma</u>		
Male	0.03	0	NC*	Male	0.49	2	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	3.24	4	NC*	Female	0.35	0	NC*
Total	3.26	4	NC*	Total	0.84	2	NC*
Cervix Uteri				Oral Cavity and Pha			
				Male	0.38	0	NC*
Female	0.20	0	NC*	Female	0.15	0	NC*
				Total	0.54	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	1.35	1	NC*				
Female	1.04	1	NC*	Female	0.38	0	NC*
Total	2.39	2	NC*				
Esophagus				<u>Pancreas</u>			
Male	0.21	0	NC*	Male	0.23	0	NC*
Female	0.05	0	NC*	Female	0.19	0	NC*
Total	0.26	0	NC*	Total	0.43	0	NC*
Hodgkin's Disease	<u>(Hodgkin Lymph</u>	<u>ioma)</u>		<u>Prostate</u>			
Male	0.10	0	NC*	Male	3.37	4	NC*
Female	0.07	0	NC*				
Total	0.17	0	NC*				
Kidney and Renal P				Stomach			
Male	0.35	0	NC*	Male	0.24	0	NC*
Female	0.18	0	NC*	Female	0.11	0	NC*
Total	0.53	0	NC*	Total	0.35	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.20	0	NC*	Male	0.16	0	NC*
Female	0.04	0	NC*				
Total	0.24	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.28	0	NC*	Male	0.09	0	NC*
Female	0.18	0	NC*	Female	0.21	1	NC*
Total	0.47	0	NC*	Total	0.30	1	NC*
Liver and Intrahepa		•	110#	Uteri, Corpus and U	terus, NOS		
Male	0.13	0	NC*				
Female	0.04	0	NC*	Female	0.62	1	NC*
Total	0.18	0	NC*	All O'Con / Torres			
Lung and Bronchus	_	4	NO*	All Sites / Types	44.00	4.4	07
Male	1.73	1	NC*	Male	11.39	11	97
Female	1.20	0	NC*	Female	9.58	10	104
Total	2.93	1	NC*	Total	20.96	21	100

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

^{* =} SIR and statistical significance not calculated when **Obs** < 5

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	1.17	0	NC*	Male	0.74	1	NC*
Female	0.40	0	NC*	Female	0.56	0	NC*
Total	1.57	0	NC*	Total	1.30	1	NC*
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.32	0	NC*	Male	0.23	0	NC*
Female	0.26	0	NC*	Female	0.18	0	NC*
Total	0.58	0	NC*	Total	0.41	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.05	0	NC*	Male	0.89	0	NC*
Female	6.63	3	NC*	Female	0.78	1	NC*
Total	6.69	3	NC*	Total	1.67	1	NC*
Cervix Uteri				Oral Cavity and Phar	<u>rynx</u>		
				Male	0.70	0	NC*
Female	0.39	1	NC*	Female	0.32	0	NC*
				Total	1.02	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	2.88	1	NC*	-			
Female	2.49	2	NC*	Female	0.78	1	NC*
Total	5.37	3	NC*				
Esophagus				<u>Pancreas</u>			
Male	0.41	0	NC*	Male	0.48	0	NC*
Female	0.12	0	NC*	Female	0.46	0	NC*
Total	0.53	0	NC*	Total	0.94	0	NC*
Hodgkin's Disease (Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	0.14	0	NC*	Male	7.02	2	NC*
Female	0.13	0	NC*				
Total	0.27	0	NC*				
Kidney and Renal Po	elvis			Stomach			
Male	0.67	0	NC*	Male	0.48	0	NC*
Female	0.40	0	NC*	Female	0.27	1	NC*
Total	1.07	0	NC*	Total	0.75	1	NC*
<u>Larynx</u>				<u>Testis</u>			
 Male	0.38	0	NC*	Male	0.20	1	NC*
Female	0.09	0	NC*				
Total	0.47	0	NC*				
<u>Leukemia</u>				Thyroid			
Male	0.53	0	NC*	 Male	0.13	0	NC*
Female	0.39	0	NC*	Female	0.40	0	NC*
Total	0.92	0	NC*	Total	0.53	0	NC*
Liver and Intrahepat				Uteri, Corpus and Ut			
Male	0.26	0	NC*				
Female	0.10	0	NC*	Female	1.28	0	NC*
Total	0.36	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	3.64	1	NC*	Male	22.86	6	26 ^-
Female	2.72	1	NC*	Female	20.61	11	53 #-
Total	6.37	2	NC*	Total	43.47	17	39 ∧-
2		-	-		-	•	

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

New Salem
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.61	0	NC*	Male	0.41	0	NC*
Female	0.19	0	NC*	Female	0.28	0	NC*
Total	0.80	0	NC*	Total	0.69	0	NC*
Brain and Other Cer	ntral Nervous S	<u>system</u>		Multiple Myeloma			
Male	0.18	0	NC*	Male	0.12	0	NC*
Female	0.12	0	NC*	Female	0.09	0	NC*
Total	0.31	0	NC*	Total	0.21	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>ıphoma</u>		
Male	0.03	0	NC*	Male	0.49	1	NC*
Female	3.33	2	NC*	Female	0.37	0	NC*
Total	3.36	2	NC*	Total	0.86	1	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	0.41	0	NC*
Female	0.19	0	NC*	Female	0.16	0	NC*
				Total	0.57	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	1.51	3	NC*				
Female	1.21	1	NC*	Female	0.38	0	NC*
Total	2.72	4	NC*				
Esophagus				<u>Pancreas</u>			
Male	0.23	0	NC*	Male	0.26	0	NC*
Female	0.06	0	NC*	Female	0.22	0	NC*
Total	0.29	0	NC*	Total	0.48	0	NC*
Hodgkin's Disease (<u>Hodgkin Lymp</u>	<u>homa)</u>		<u>Prostate</u>			
Male	0.08	0	NC*	Male	3.94	3	NC*
Female	0.06	0	NC*				
Total	0.14	0	NC*				
Kidney and Renal P				<u>Stomach</u>			
Male	0.38	1	NC*	Male	0.26	0	NC*
Female	0.19	0	NC*	Female	0.13	0	NC*
Total	0.57	1	NC*	Total	0.39	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.22	0	NC*	Male	0.10	0	NC*
Female	0.05	0	NC*				
Total	0.27	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.29	0	NC*	Male	0.08	0	NC*
Female	0.19	0	NC*	Female	0.19	0	NC*
Total	0.48	0	NC*	Total	0.27	0	NC*

Liver and Intrahepat	ic Bile Ducts			Uteri, Corpus and Uterus, NOS			
Male	0.15	0	NC*				
Female	0.05	0	NC*	Female	0.64	0	NC*
Total	0.20	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	1.97	0	NC*	Male	12.54	9	72
Female	1.29	3	NC*	Female	10.12	6	59
Total	3.26	3	NC*	Total	22.66	15	66

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

Newbury
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.87	1	NC*	Male	2.83	1	NC*
Female	1.50	1	NC*	Female	2.12	1	NC*
Total	5.38	2	NC*	Total	4.95	2	NC*
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.29	1	NC*	Male	0.81	1	NC*
Female	1.00	2	NC*	Female	0.71	1	NC*
Total	2.29	3	NC*	Total	1.51	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.20	0	NC*	Male	3.32	4	NC*
Female	26.13	32	122	Female	2.94	4	NC*
Total	26.33	32	122	Total	6.26	8	128
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	2.81	3	NC*
Female	1.43	3	NC*	Female	1.27	3	NC*
				Total	4.08	6	147
Colon / Rectum				<u>Ovary</u>			
Male	9.79	11	112				
Female	9.40	15	160	Female	3.02	2	NC*
Total	19.19	26	136				
Esophagus				<u>Pancreas</u>			
Male	1.56	1	NC*	Male	1.72	2	NC*
Female	0.46	0	NC*	Female	1.74	3	NC*
Total	2.02	1	NC*	Total	3.46	5	144
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		Prostate			
Male	0.61	1	NC*	Male	26.56	28	105
Female	0.46	1	NC*				
Total	1.06	2	NC*				
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	2.55	0	NC*	Male	1.68	1	NC*
Female	1.54	0	NC*	Female	1.01	0	NC*
Total	4.09	0	NC*	Total	2.69	1	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.51	1	NC*	Male	0.86	1	NC*
Female	0.37	0	NC*				
Total	1.87	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.91	2	NC*	Male	0.58	0	NC*
Female	1.51	2	NC*	Female	1.44	1	NC*
Total	3.42	4	NC*	Total	2.02	1	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	0.99	0	NC*				
Female	0.39	0	NC*	Female	5.13	7	137
Total	1.38	0	NC*				
Lung and Bronchus	<u>3</u>			All Sites / Types			
Male	13.12	7	53	Male	83.92	73	87
Female	10.52	12	114	Female	79.63	94	118
Total	23.64	19	80	Total	163.56	167	102

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} < 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Newburyport
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	10.16	8	79	Male	7.15	8	112
Female	4.47	2	NC*	Female	6.03	15	249 ~+
Total	14.64	10	68	Total	13.18	23	175 #+
Brain and Other Cer	ntral Nervous S	<u>system</u>		Multiple Myeloma			
Male	3.19	3	NC*	Male	2.04	1	NC*
Female	2.76	5	181	Female	2.02	3	NC*
Total	5.95	8	134	Total	4.06	4	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.49	0	NC*	Male	8.52	14	164
Female	72.73	79	109	Female	8.46	10	118
Total	73.22	79	108	Total	16.98	24	141
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	6.83	4	NC*
Female	4.07	3	NC*	Female	3.58	7	195
				Total	10.42	11	106
Colon / Rectum				<u>Ovary</u>			
Male	25.30	30	119				

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	28.04	34	121	Female	8.42	10	119
Total	53.34	64	120				
Esophagus				<u>Pancreas</u>			
Male	3.81	4	NC*	Male	4.36	6	138
Female	1.36	1	NC*	Female	5.15	6	117
Total	5.18	5	97	Total	9.51	12	126
Hodgkin's Disease	(Hodgkin Lympl	homa <u>)</u>		Prostate			
Male	1.59	2	NC*	Male	63.72	59	93
Female	1.32	2	NC*				
Total	2.92	4	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	6.30	1	NC*	Male	4.38	2	NC*
Female	4.32	5	116	Female	3.06	3	NC*
Total	10.62	6	56	Total	7.44	5	67
<u>Larynx</u>				<u>Testis</u>			
Male	3.61	3	NC*	Male	2.40	2	NC*
Female	1.00	1	NC*				
Total	4.61	4	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	4.90	6	122	Male	1.46	1	NC*
Female	4.30	6	140	Female	4.11	2	NC*
Total	9.20	12	130	Total	5.56	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	2.43	1	NC*				
Female	1.12	0	NC*	Female	14.04	14	100
Total	3.56	1	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	32.40	41	127	Male	209.06	210	100
Female	29.44	37	126	Female	226.22	270	119 ~-
Total	61.84	78	126	Total	435.29	480	110 #+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Newton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	59.57	51	86	Male	39.54	43	109
Female	24.08	15	62	Female	32.60	46	141 #+
Total	83.65	66	79	Total	72.14	89	123
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	17.37	12	69	Male	11.58	18	155
Female	15.06	13	86	Female	10.77	16	148

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Tota	I 32.44	25	77	Total	22.36	34	152 #+
Breast	1 32.44	25	11	Non-Hodgkin('s) Ly		34	132 #+
Male	2.78	1	NC*	Male	47.75	65	136 #+
Female		448	116 ~+	Female	45.69	65	142 ~+
Tota		449	115 ~+	Total	93.45	130	142 ~ + 139 ^+
Cervix Uteri	1 303.33	443	115~+	Oral Cavity and Pha		130	100 // +
CEIVIX OLEIT				Male	36.84	26	71
Female	22.27	9	40 ~-	Female	19.12	18	94
i Giliale	22.21	3	40 ~-	Total	55.96	44	79
Colon / Rectur	m			<u>Ovary</u>	33.30	77	13
Male		124	84	<u>Ovary</u>			
Female		144	95	Female	45.02	55	122
Tota		268	90	Tomaio	40.02	00	122
Esophagus	200.00	200	30	<u>Pancreas</u>			
Male	21.19	16	76	Male	24.92	22	88
Female		11	150	Female	27.70	25	90
Tota		27	95	Total	52.62	47	89
	ease (Hodgkin Ly			<u>Prostate</u>	02.02		00
Male		11	126	Male	362.90	347	96
Female		13	173			•	
Tota		24	148				
Kidney and Re				<u>Stomach</u>			
Male		33	95	Male	25.17	22	87
Female		28	121	Female	16.53	8	48 #-
Tota		61	105	Total	41.70	30	72
<u>Larynx</u>				<u>Testis</u>			
Male	e 19.77	9	46 #-	Male	13.37	15	112
Female	5.27	3	NC*				
Tota	1 25.04	12	48 ~-				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	27.64	37	134	Male	7.82	18	230 ~+
Female	23.25	37	159 #+	Female	22.73	23	101
Tota	I 50.89	74	145 ~+	Total	30.55	41	134
Liver and Intra	hepatic Bile Duct	<u>s</u>		Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	13.46	8	59				
Female	6.04	6	99	Female	74.09	62	84
Tota	l 19.51	14	72				
Lung and Bron	<u>nchus</u>			All Sites / Types			
Male		127	68 ^-	Male	1189.38	1081	91 ~-
Female		140	89	Female	1211.49	1263	104
Tota	I 343.22	267	78 ^-	Total	2400.87	2344	98

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Norfolk Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	4.85	4	NC*	Male	4.45	8	180
Female	1.17	3	NC*	Female	2.23	5	224
Total	6.02	7	116	Total	6.68	13	194 #+
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	2.16	1	NC*	Male	1.07	0	NC*
Female	1.08	1	NC*	Female	0.60	0	NC*
Total	3.24	2	NC*	Total	1.67	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.26	0	NC*	Male	5.17	4	NC*
Female	26.18	28	107	Female	2.63	2	NC*
Total	26.45	28	106	Total	7.80	6	77
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	4.25	1	NC*
Female	1.65	1	NC*	Female	1.19	0	NC*
				Total	5.45	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	12.49	10	80				
Female	7.24	3	NC*	Female	3.09	1	NC*
Total	19.73	13	66				
Esophagus				<u>Pancreas</u>			
Male	2.14	3	NC*	Male	2.28	1	NC*
Female	0.35	0	NC*	Female	1.36	1	NC*
Total	2.49	3	NC*	Total	3.64	2	NC*
Hodgkin's Disease (Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	1.30	1	NC*	Male	33.94	32	94
Female	0.56	2	NC*				
Total	1.86	3	NC*				
Kidney and Renal Po	<u>elvis</u>			<u>Stomach</u>			
Male	3.72	5	135	Male	2.22	2	NC*
Female	1.42	1	NC*	Female	0.79	0	NC*
Total	5.14	6	117	Total	3.01	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.13	1	NC*	Male	2.23	3	NC*
Female	0.35	2	NC*				
Total	2.48	3	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.84	3	NC*	Male	1.11	1	NC*
Female	1.49	2	NC*	Female	1.74	2	NC*
Total	4.33	5	116	Total	2.86	3	NC*
Liver and Intrahepat				Uteri, Corpus and Ut	<u>terus, NOS</u>		
Male	1.43	0	NC*				
Female	0.32	0	NC*	Female	5.06	5	99
Total	1.75	0	NC*				
Lung and Bronchus			_	All Sites / Types			
Male	16.95	10	59	Male	114.74	96	84
Female	9.25	5	54	Female	74.57	69	93
Total	26.20	15	57 #-	Total	189.31	165	87

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

North Adams
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary	-			Melanoma of Skin			
Male	10.92	12	110	Male	6.94	6	86
Female	5.31	5	94	Female	6.15	4	NC*
Total	16.23	17	105	Total	13.09	10	76
Brain and Other O	Central Nervous S	<u>System</u>		Multiple Myeloma			
Male	3.08	4	NC*	Male	2.07	1	NC*
Female	2.94	1	NC*	Female	2.28	2	NC*
Total	6.03	5	83	Total	4.34	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyı	mphoma		
Male	0.50	0	NC*	Male	8.52	7	82
Female	73.79	76	103	Female	9.53	13	136
Total	74.29	76	102	Total	18.04	20	111
Cervix Uteri				Oral Cavity and Pha			
				Male	6.32	10	158
Female	3.95	5	127	Female	3.82	1	NC*
				Total	10.15	11	108
Colon / Rectum				<u>Ovary</u>			
Male	26.97	37	137				
Female	33.53	37	110	Female	8.56	8	93
Total	60.49	74	122				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	3.73	2	NC*	Male	4.48	8	178
Female	1.63	5	306	Female	6.11	4	NC*
Total	5.36	7	131	Total	10.59	12	113
Hodgkin's Diseas				<u>Prostate</u>			
Male	1.58	2	NC*	Male	65.40	74	113
Female	1.38	1	NC*				
Total	2.96	3	NC*				
Kidney and Renal				<u>Stomach</u>			
Male	6.09	10	164	Male	4.55	4	NC*
Female	4.69	10	213 #+	Female	3.65	5	137
Total	10.78	20	186 #+	Total	8.20	9	110
<u>Larynx</u>				<u>Testis</u>			
Male	3.44	1	NC*	Male	2.42	0	NC*
Female	1.03	1	NC*				
Total	4.47	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	5.02	7	139	Male	1.35	0	NC*
Female	4.77	4	NC*	Female	3.95	5	127
Total	9.80	11	112	Total	5.30	5	94
Liver and Intra	hepatic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	2.37	2	NC*				
Female	1.31	0	NC*	Female	14.19	21	148
Total	3.68	2	NC*				
Lung and Bron	<u>ichus</u>			All Sites / Types			
Male	33.68	38	113	Male	214.11	244	114 #+
Female	32.59	33	101	Female	244.04	261	107
Total	66.27	71	107	Total	458.15	505	110 #+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

North Andover
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	14.29	14	98	Male	10.39	15	144
Female	5.74	10	174	Female	8.36	3	NC*
Total	20.03	24	120	Total	18.75	18	96
Brain and Other Co	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	4.82	4	NC*	Male	2.92	2	NC*
Female	3.97	5	126	Female	2.69	4	NC*
Total	8.79	9	102	Total	5.61	6	107
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.71	1	NC*	Male	12.36	9	73
Female	100.32	83	83	Female	11.41	11	96
Total	101.02	84	83	Total	23.78	20	84
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	10.03	7	70
Female	5.80	7	121	Female	4.85	3	NC*
				Total	14.88	10	67
Colon / Rectum				<u>Ovary</u>			
Male	35.91	29	81				
Female	35.96	36	100	Female	11.71	15	128
Total	71.87	65	90				
Esophagus				<u>Pancreas</u>			
Male	5.56	8	144	Male	6.24	9	144
Female	1.74	2	NC*	Female	6.66	5	75
Total	7.30	10	137	Total	12.90	14	109
Hodgkin's Disease	(Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	2.43	2	NC*	Male	93.92	109	116

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	1.94	1	NC*				
Total	4.37	3	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	9.20	9	98	Male	6.17	5	81
Female	5.89	4	NC*	Female	3.86	2	NC*
Total	15.09	13	86	Total	10.03	7	70
<u>Larynx</u>				<u>Testis</u>			
Male	5.32	6	113	Male	3.64	5	137
Female	1.39	0	NC*				
Total	6.71	6	89				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	7.18	3	NC*	Male	2.18	3	NC*
Female	5.84	7	120	Female	5.94	11	185
Total	13.02	10	77	Total	8.13	14	172
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	3.57	7	196				
Female	1.48	0	NC*	Female	19.47	20	103
Total	5.04	7	139				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	47.11	44	93	Male	304.04	312	103
Female	40.28	36	89	Female	306.76	293	96
Total	87.40	80	92	Total	610.81	605	99

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

North Attleborough
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	13.96	12	86	Male	10.24	16	156
Female	5.16	1	NC*	Female	8.00	5	62
Total	19.11	13	68	Total	18.24	21	115
Brain and Other Cer	itral Nervous S	<u>system</u>		Multiple Myeloma			
Male	4.77	6	126	Male	2.81	2	NC*
Female	3.79	3	NC*	Female	2.40	1	NC*
Total	8.56	9	105	Total	5.20	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.68	0	NC*	Male	12.27	7	57
Female	92.11	96	104	Female	10.48	10	95
Total	92.79	96	103	Total	22.76	17	75
Cervix Uteri				Oral Cavity and Pha	rynx		
				Male	9.59	11	115
Female	5.76	4	NC*	Female	4.42	9	204

^{* =} SIR and statistical significance not calculated when **Obs** < 5

				Total	14.01	20	143
Colon / Rectum				<u>Ovary</u>			
Male	34.96	34	97				
Female	32.32	41	127	Female	10.90	16	147
Total	67.28	75	111				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	5.28	5	95	Male	6.03	5	83
Female	1.56	4	NC*	Female	5.95	6	101
Total	6.84	9	132	Total	11.99	11	92
Hodgkin's Disease	(Hodgkin Lympl	<u>noma)</u>		<u>Prostate</u>			
Male	2.59	2	NC*	Male	88.51	52	59 ^-
Female	2.03	2	NC*				
Total	4.62	4	NC*				
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>			
Male	8.82	7	79	Male	6.04	1	NC*
Female	5.34	0	NC*	Female	3.52	2	NC*
Total	14.16	7	49	Total	9.56	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	5.02	3	NC*	Male	4.14	2	NC*
Female	1.24	1	NC*				
Total	6.26	4	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	7.08	5	71	Male	2.22	0	NC*
Female	5.49	6	109	Female	6.05	8	132
Total	12.57	11	88	Total	8.28	8	97
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	3.41	1	NC*				
Female	1.33	0	NC*	Female	17.53	10	57
Total	4.75	1	NC*				
Lung and Bronchus	<u>i</u>			All Sites / Types			
Male	44.96	48	107	Male	293.39	244	83 ~-
Female	35.79	42	117	Female	280.86	287	102
Total	80.75	90	111	Total	574.25	531	92

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

North Brookfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.02	2	NC*	Male	2.07	2	NC*
Female	1.10	1	NC*	Female	1.54	2	NC*
Total	4.12	3	NC*	Total	3.61	4	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Brain and Other Ce	ntral Nervous Sy	<u>ystem</u>		Multiple Myeloma			
Male	0.93	4	NC*	Male	0.59	0	NC*
Female	0.74	0	NC*	Female	0.50	0	NC*
Total	1.68	4	NC*	Total	1.10	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	0.14	0	NC*	Male	2.50	4	NC*
Female	18.10	21	116	Female	2.15	1	NC*
Total	18.25	21	115	Total	4.66	5	107
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	1.90	0	NC*
Female	1.07	1	NC*	Female	0.89	0	NC*
				Total	2.79	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	7.47	8	107				
Female	6.93	5	72	Female	2.13	0	NC*
Total	14.41	13	90				
Esophagus				<u>Pancreas</u>			
Male	1.07	0	NC*	Male	1.26	0	NC*
Female	0.34	0	NC*	Female	1.27	1	NC*
Total	1.41	0	NC*	Total	2.53	1	NC*
Hodgkin's Disease	(Hodgkin Lymph	noma)		<u>Prostate</u>			
Male	0.49	0	NC*	Male	18.04	16	89
Female	0.38	1	NC*				
Total	0.87	1	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	1.80	3	NC*	Male	1.28	1	NC*
Female	1.08	0	NC*	Female	0.75	1	NC*
Total	2.89	3	NC*	Total	2.03	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.01	0	NC*	Male	0.77	0	NC*
Female	0.25	0	NC*				
Total	1.25	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.47	1	NC*	Male	0.42	0	NC*
Female	1.11	0	NC*	Female	1.11	1	NC*
Total	2.57	1	NC*	Total	1.53	1	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	0.69	0	NC*				
Female	0.28	0	NC*	Female	3.47	6	173
Total	0.97	0	NC*				
Lung and Bronchus	<u> </u>			All Sites / Types			
Male	9.38	11	117	Male	60.52	54	89
Female	7.40	7	95	Female	56.70	56	99
Total	16.79	18	107	Total	117.22	110	94

Obs = observed case count

^{* =} SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

[–] indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level

~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

 \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

North Reading
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	7.16	2	NC*	Male	5.23	9	172
Female	2.55	2	NC*	Female	3.94	4	NC*
Total	9.71	4	NC*	Total	9.18	13	142
Brain and Other Cen	tral Nervous S	ystem		Multiple Myeloma			
Male	2.44	1	NC*	Male	1.47	1	NC*
Female	1.87	3	NC*	Female	1.22	0	NC*
Total	4.30	4	NC*	Total	2.69	1	NC*
Breast		·		Non-Hodgkin('s) Lyn		•	
Male	0.36	0	NC*	Male	6.20	3	NC*
Female	47.39	42	89	Female	5.22	6	115
Total	47.75	42	88	Total	11.42	9	79
Cervix Uteri	-			Oral Cavity and Pha		-	
				Male	5.09	4	NC*
Female	2.79	0	NC*	Female	2.26	3	NC*
Tomalo	2.70	· ·	140	Total	7.34	7	95
Colon / Rectum				Ovary	7.54	,	55
Male	18.12	22	121	<u>Ovary</u>			
Female	15.91	11	69	Female	5.54	3	NC*
Total	34.03	33	97	remale	3.34	3	INC
	34.03	33	91	Danaraaa			
<u>Esophagus</u>	0.04	0	NO*	<u>Pancreas</u>	2.40	0	NOt
Male	2.84	2	NC*	Male	3.16	2	NC*
Female	0.77	2	NC*	Female	2.98	0	NC*
Total	3.61	4	NC*	Total	6.13	2	NC*
Hodgkin's Disease (I		<u>homa)</u>		<u>Prostate</u>			
Male	1.21	1	NC*	Male	48.87	49	100
Female	0.92	1	NC*				
Total	2.14	2	NC*				
Kidney and Renal Pe	<u>elvis</u>			<u>Stomach</u>			
Male	4.66	5	107	Male	3.08	1	NC*
Female	2.74	6	219	Female	1.71	0	NC*
Total	7.39	11	149	Total	4.79	1	NC*
Larynx				<u>Testis</u>			
Male	2.73	1	NC*	Male	1.82	4	NC*
Female	0.66	0	NC*				
Total	3.39	1	NC*				
<u>Leukemia</u>	0.00	·		<u>Thyroid</u>			
Male	3.58	4	NC*	Male	1.10	0	NC*
Female	2.69	1	NC*	Female	2.87	4	NC*
Total	6.27	5	80	Total	3.97	4	NC*
Liver and Intrahepat		J	00	Uteri, Corpus and Ut		7	NO
-		4	NO*	oten, corpus and ot	leius, NUS		
Male	1.82	1	NC*	F a 1 .	0.00	4	NIO+
Female	0.67	0	NC*	Female	9.23	4	NC*
Total	2.48	1	NC*	A11 614 / =			
Lung and Bronchus	0.4.0.4	a =	400	All Sites / Types	4== 40		•
Male	24.21	25	103	Male	155.18	141	91

Female	18.65	20	107	Female	142.22	122	86
Total	42.87	45	105	Total	297.40	263	88 #-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Northampton
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

Exp Obs SIR Bladder, Urinary Melanoma of Skin Male 17.94 14 78 Male 12.10 11 91 Female 7.81 9 115 Female 10.67 11 103 Total 25.76 23 89 Total 22.78 22 97
Male 17.94 14 78 Male 12.10 11 91 Female 7.81 9 115 Female 10.67 11 103
Female 7.81 9 115 Female 10.67 11 103
Total 25.76 23 89 Total 22.78 22 97
1001 2010 20 00 1001
Brain and Other Central Nervous System Multiple Myeloma
Male 5.31 5 94 Male 3.50 9 257 #+
Female 4.92 3 NC* Female 3.41 3 NC*
Total 10.23 8 78 Total 6.91 12 174
Breast Non-Hodgkin('s) Lymphoma
Male 0.84 0 NC* Male 14.59 12 82
Female 121.00 107 88 Female 14.80 13 88
Total 121.84 107 88 Total 29.39 25 85
Cervix Uteri Oral Cavity and Pharynx
Male 11.17 11 98
Female 7.46 2 NC* Female 6.03 7 116
Total 17.21 18 105
Colon / Rectum Ovary
Male 44.44 43 97
Female 49.32 39 79 Female 14.27 15 105
Total 93.76 82 87
<u>Esophagus</u> <u>Pancreas</u>
Male 6.37 9 141 Male 7.50 1 NC*
Female 2.39 2 NC* Female 8.92 6 67
Total 8.76 11 126 Total 16.42 7 43 #-
Hodgkin's Disease (Hodgkin Lymphoma) Prostate
Male 2.76 4 NC* Male 108.53 91 84
Female 2.68 3 NC*
Total 5.44 7 129
Kidney and Renal Pelvis Stomach
Male 10.54 13 123 Male 7.59 3 NC*
Female 7.26 12 165 Female 5.46 4 NC*
Total 17.80 25 140 Total 13.05 7 54
<u>Larynx</u> <u>Testis</u>
Male 5.96 5 84 Male 4.36 3 NC*
Female 1.59 1 NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	7.55	6	79				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.37	6	72	Male	2.44	2	NC*
Female	7.59	4	NC*	Female	7.80	8	103
Total	15.96	10	63	Total	10.24	10	98
Liver and Intrahepatic Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	4.07	2	NC*				
Female	1.94	0	NC*	Female	22.64	23	102
Total	6.01	2	NC*				
Lung and Bronchu	<u>IS</u>			All Sites / Types			
Male	55.96	53	95	Male	358.86	321	89 #-
Female	48.76	41	84	Female	385.73	336	87 #-
Total	104.72	94	90	Total	744.59	657	88 ~-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

Northborough
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	6.95	7	101	Male	5.33	7	131
Female	2.41	3	NC*	Female	3.94	4	NC*
Total	9.36	10	107	Total	9.27	11	119
Brain and Other Cer	<u>ntral Nervous S</u>	<u>System</u>		Multiple Myeloma			
Male	2.50	2	NC*	Male	1.46	1	NC*
Female	1.86	1	NC*	Female	1.17	1	NC*
Total	4.35	3	NC*	Total	2.63	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.35	0	NC*	Male	6.27	10	159
Female	47.16	52	110	Female	5.03	3	NC*
Total	47.52	52	109	Total	11.30	13	115
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	5.19	5	96
Female	2.82	1	NC*	Female	2.22	4	NC*
				Total	7.41	9	121
Colon / Rectum				<u>Ovary</u>			
Male	17.60	10	57				
Female	14.96	16	107	Female	5.52	5	91
Total	32.56	26	80				
Esophagus				<u>Pancreas</u>			
Male	2.82	1	NC*	Male	3.10	1	NC*
Female	0.73	0	NC*	Female	2.80	5	178
Total	3.54	1	NC*	Total	5.90	6	102

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Hodgkin's Disease	Hodgkin Lympl	noma <u>)</u>		Prostate				
Male	1.28	2	NC*	Male	47.14	46	98	
Female	0.93	1	NC*					
Total	2.21	3	NC*					
Kidney and Renal P	<u>elvis</u>			Stomach				
Male	4.70	3	NC*	Male	3.04	0	NC*	
Female	2.67	0	NC*	Female	1.62	0	NC*	
Total	7.36	3	NC*	Total	4.66	0	NC*	
<u>Larynx</u>				<u>Testis</u>				
Male	2.73	0	NC*	Male	1.96	0	NC*	
Female	0.65	1	NC*					
Total	3.38	1	NC*					
<u>Leukemia</u>				<u>Thyroid</u>				
Male	3.60	3	NC*	Male	1.16	0	NC*	
Female	2.67	1	NC*	Female	2.91	3	NC*	
Total	6.27	4	NC*	Total	4.07	3	NC*	
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	1.82	2	NC*					
Female	0.64	1	NC*	Female	9.15	11	120	
Total	2.45	3	NC*					
Lung and Bronchus	<u>i</u>			All Sites / Types				
Male	23.48	16	68	Male	152.45	129	85	
Female	17.84	8	45 #-	Female	139.00	125	90	
Total	41.32	24	58 ~-	Total	291.46	254	87 #-	

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Northbridge
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	8.34	5	60	Male	5.55	7	126
Female	3.45	4	NC*	Female	4.53	8	177
Total	11.79	9	76	Total	10.08	15	149
Brain and Other Central Nervous System				Multiple Myeloma			
Male	2.51	3	NC*	Male	1.61	1	NC*
Female	2.16	0	NC*	Female	1.52	0	NC*
Total	4.68	3	NC*	Total	3.13	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	<u>mphoma</u>		
Male	0.39	0	NC*	Male	6.76	5	74
Female	52.77	55	104	Female	6.48	5	77
Total	53.16	55	103	Total	13.25	10	75
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

				Male	5.13	5	97
Female	3.07	5	163	Female	2.65	2	NC*
				Total	7.78	7	90
Colon / Rectum				<u>Ovary</u>			
Male	20.63	15	73				
Female	21.76	19	87	Female	6.19	5	81
Total	42.39	34	80				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	2.94	3	NC*	Male	3.48	6	172
Female	1.05	4	NC*	Female	3.95	9	228 #+
Total	4.00	7	175	Total	7.43	15	202 #+
Hodgkin's Disease	(Hodgkin Lympl	noma)		<u>Prostate</u>			
Male	1.30	1	NC*	Male	50.20	52	104
Female	1.10	0	NC*				
Total	2.39	1	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	4.86	2	NC*	Male	3.53	3	NC*
Female	3.21	5	156	Female	2.38	1	NC*
Total	8.07	7	87	Total	5.91	4	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.74	0	NC*	Male	1.98	2	NC*
Female	0.71	1	NC*				
Total	3.45	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.99	3	NC*	Male	1.11	3	NC*
Female	3.37	1	NC*	Female	3.17	5	158
Total	7.36	4	NC*	Total	4.28	8	187
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.88	2	NC*				
Female	0.86	0	NC*	Female	10.03	6	60
Total	2.74	2	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	25.84	20	77	Male	166.24	149	90
Female	21.78	24	110	Female	168.93	164	97
Total	47.63	44	92	Total	335.17	313	93

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Northfield Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	2.02	1	NC*	Male	1.35	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	0.83	0	NC*	Female	1.05	0	NC*
Total	2.85	1	NC*	Total	2.40	0	NC*
Brain and Other Ce		•		Multiple Myeloma	2.10	v	
Male	0.59	0	NC*	Male	0.40	0	NC*
Female	0.49	0	NC*	Female	0.37	0	NC*
Total	1.08	0	NC*	Total	0.77	0	NC*
Breast				Non-Hodgkin('s) Lyr			
 Male	0.10	1	NC*	Male	1.61	1	NC*
Female	12.81	13	102	Female	1.53	3	NC*
Total	12.90	14	109	Total	3.15	4	NC*
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	1.30	0	NC*
Female	0.69	1	NC*	Female	0.64	0	NC*
				Total	1.94	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	5.02	3	NC*	•			
Female	5.22	4	NC*	Female	1.48	1	NC*
Total	10.24	7	68				
Esophagus				<u>Pancreas</u>			
Male	0.75	1	NC*	Male	0.86	2	NC*
Female	0.25	0	NC*	Female	0.96	1	NC*
Total	1.00	1	NC*	Total	1.82	3	NC*
Hodgkin's Disease	(Hodgkin Lymph	noma)		Prostate			
Male	0.27	0	NC*	Male	12.67	10	79
Female	0.23	0	NC*				
Total	0.50	0	NC*				
Kidney and Renal F	<u>Pelvis</u>			Stomach			
Male	1.21	0	NC*	Male	0.86	2	NC*
Female	0.78	1	NC*	Female	0.57	1	NC*
Total	1.99	1	NC*	Total	1.43	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.70	0	NC*	Male	0.38	2	NC*
Female	0.18	0	NC*				
Total	0.88	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.94	1	NC*	Male	0.26	1	NC*
Female	0.78	0	NC*	Female	0.69	3	NC*
Total	1.72	1	NC*	Total	0.95	4	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and Ut	terus, NOS		
Male	0.47	0	NC*				
Female	0.21	0	NC*	Female	2.48	4	NC*
Total	0.68	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	6.41	4	NC*	Male	40.86	32	78
Female	5.33	2	NC*	Female	40.59	37	91
Total	11.74	6	51	Total	81.45	69	85

Obs = observed case count

 $^{^{\}star}$ = SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

NortonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	6.84	7	102	Male	5.34	5	94
Female	2.66	3	NC*	Female	4.55	8	176
Total	9.50	10	105	Total	9.89	13	132
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	2.59	3	NC*	Male	1.43	1	NC*
Female	2.19	2	NC*	Female	1.26	2	NC*
Total	4.78	5	105	Total	2.69	3	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Male	0.35	0	NC*	Male	6.35	2	NC*
Female	51.12	45	88	Female	5.65	7	124
Total	51.47	45	87	Total	12.00	9	75
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	5.13	7	136
Female	3.36	2	NC*	Female	2.41	0	NC*
				Total	7.54	7	93
Colon / Rectum				<u>Ovary</u>			
Male	17.31	21	121				
Female	16.64	12	72	Female	6.11	6	98
Total	33.95	33	97				
Esophagus				<u>Pancreas</u>			
Male	2.75	2	NC*	Male	3.05	1	NC*
Female	0.80	0	NC*	Female	3.06	6	196
Total	3.55	2	NC*	Total	6.10	7	115
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	1.39	1	NC*	Male	45.64	26	57 ~-
Female	1.22	0	NC*				
Total	2.61	1	NC*				
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>			
Male	4.65	4	NC*	Male	3.01	3	NC*
Female	2.89	4	NC*	Female	1.83	1	NC*
Total	7.54	8	106	Total	4.83	4	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.66	6	225	Male	2.17	1	NC*
Female	0.67	0	NC*				
Total	3.33	6	180				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.71	2	NC*	Male	1.20	0	NC*
Female	3.10	1	NC*	Female	3.60	1	NC*
Total	6.81	3	NC*	Total	4.80	1	NC*
Liver and Intrahepa				Uteri, Corpus and Ut	terus, NOS		
Male	1.80	5	279				
Female	0.70	1	NC*	Female	9.64	11	114

Total	2.49	6	241				
Lung and Bronchus				All Sites / Types			
Male	22.89	17	74	Male	150.35	119	79 ~-
Female	18.90	28	148	Female	152.91	150	98
Total	41.79	45	108	Total	303.27	269	89 #-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** < 0.001 level, as well as at the **p** < 0.05 and **p** < 0.01 levels

Norwell
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	•		,		•		
	Exp	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	6.38	7	110	Male	4.66	7	150
Female	2.15	3	NC*	Female	3.35	5	149
Total	8.53	10	117	Total	8.01	12	150
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	2.13	1	NC*	Male	1.33	1	NC*
Female	1.58	2	NC*	Female	1.07	1	NC*
Total	3.71	3	NC*	Total	2.39	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyr	mphoma		
Male	0.32	0	NC*	Male	5.47	3	NC*
Female	41.97	43	102	Female	4.44	4	NC*
Total	42.29	43	102	Total	9.91	7	71
Cervix Uteri				Oral Cavity and Pharynx			
				Male	4.63	5	108
Female	2.32	1	NC*	Female	1.97	1	NC*
				Total	6.61	6	91
Colon / Rectum				<u>Ovary</u>			
Male	16.12	17	105				
Female	13.34	12	90	Female	4.85	3	NC*
Total	29.46	29	98				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	2.57	1	NC*	Male	2.83	3	NC*
Female	0.65	0	NC*	Female	2.52	2	NC*
Total	3.22	1	NC*	Total	5.35	5	93
Hodgkin's Disease				<u>Prostate</u>			
Male	1.00	0	NC*	Male	43.61	46	105
Female	0.71	0	NC*				
Total	1.71	0	NC*				
Kidney and Renal P				<u>Stomach</u>			
Male	4.20	4	NC*	Male	2.76	2	NC*
Female	2.40	4	NC*	Female	1.41	2	NC*
Total	6.60	8	121	Total	4.17	4	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

<u>Larynx</u>				<u>Testis</u>			
Male	2.48	1	NC*	Male	1.41	0	NC*
Female	0.60	0	NC*				
Total	3.08	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.15	2	NC*	Male	0.96	4	NC*
Female	2.27	3	NC*	Female	2.33	5	215
Total	5.42	5	92	Total	3.29	9	274 #+
Liver and Intrahepatic Bile Ducts				Uteri, Corpus and Uterus, NOS			
Male	1.64	3	NC*				
Female	0.57	0	NC*	Female	8.33	8	96
Total	2.20	3	NC*				
Lung and Bronchus				All Sites / Types			
Male	21.56	11	51 #-	Male	138.04	123	89
Female	16.47	9	55	Female	123.39	116	94
Total	38.03	20	53 ~-	Total	261.43	239	91

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

NorwoodExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	19.31	23	119	Male	12.58	22	175 #+
Female	8.72	8	92	Female	10.74	13	121
Total	28.03	31	111	Total	23.31	35	150 #+
Brain and Other Central Nervous System			Multiple Myeloma				
Male	5.58	8	143	Male	3.71	2	NC*
Female	5.00	3	NC*	Female	3.77	2	NC*
Total	10.58	11	104	Total	7.48	4	NC*
<u>Breast</u>				Non-Hodgkin('s) Lymphoma			
Male	0.89	2	NC*	Male	15.30	16	105
Female	127.33	129	101	Female	15.95	18	113
Total	128.23	131	102	Total	31.25	34	109
Cervix Uteri			Oral Cavity and Pharynx				
				Male	11.45	7	61
Female	7.13	5	70	Female	6.49	1	NC*
				Total	17.93	8	45 #-
Colon / Rectum				<u>Ovary</u>			
Male	47.88	66	138 #+				
Female	54.81	66	120	Female	14.82	12	81
Total	102.69	132	129 ~+				
<u>Esophagus</u>				<u>Pancreas</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	6.69	13	194 #+	Male	7.96	8	100
Female	2.68	3	NC*	Female	10.05	7	70
Total	9.37	16	171	Total	18.01	15	83
Hodgkin's Disease (Hodgkin Lymphoma)				Prostate			
Male	2.89	1	NC*	Male	117.74	128	109
Female	2.47	2	NC*				
Total	5.36	3	NC*				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	11.02	11	100	Male	8.01	14	175
Female	7.92	10	126	Female	6.00	13	217 #+
Total	18.94	21	111	Total	14.02	27	193 ~+
<u>Larynx</u>				<u>Testis</u>			
Male	6.24	12	192	Male	4.56	7	154
Female	1.76	3	NC*				
Total	8.00	15	187 #+				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	8.92	13	146	Male	2.49	3	NC*
Female	7.95	8	101	Female	7.22	11	152
Total	16.88	21	124	Total	9.70	14	144
Liver and Intrahepatic Bile Ducts				Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	4.28	4	NC*				
Female	2.16	1	NC*	Female	24.37	33	135
Total	6.44	5	78				
Lung and Bronchu	<u>IS</u>			All Sites / Types			
Male	60.61	74	122	Male	384.23	460	120 ^+
Female	54.64	64	117	Female	413.23	457	111 #+
Total	115.25	138	120 #+	Total	797.45	917	115 ^+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels

^{* =} SIR and statistical significance not calculated when **Obs** < 5